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ABSTRACT OF DISSERTATION

DELINEATING THE ROLE OF FATTY ACID METABOLISM TO IMPROVE
THERAPEUTIC STRATEGIES FOR COLORECTAL CANCER

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths
in the world, comprising over 1 million new cases each year and over 500,000
deaths. CRC, when detected at an early stage of disease development, can be
effectively treated, with a 5-year survival rate of over 90%. Such standard
treatments include surgical resection of the primary tumor in combination with
adjuvant chemotherapy. However, even with advancements in surgical procedures
and chemotherapeutic targets, when CRC progresses to a more advance stage,
the 5-year survival rate decreases significantly to just under 14%. This stark
decrease in patient survival rate can be directly contributed to the lack of effective
chemotherapeutics as well as relapse, which occurs in 30-50% of patients treated
for CRC and results in a far more aggressive disease. With such a large rate of
CRC relapse and drastically low survival rates, the need for new therapeutic
targets for the disease are particularly needed.
Dysregulation of fatty acid (FA) metabolism has been identified as a
hallmark of cancer and a key proponent to CRC development and progression.
FAs are used for a multitude of purposes within the cell, such as signaling
molecules, components of membrane synthesis, and most importantly, as a direct
energy source. Two different pathways contribute to FA utilization in cancer cells.
First, FAs can be synthesized de novo. FA Synthase (FASN), a key enzyme of de
novo FA synthesis, catalyzes the synthesis of palmitate from acetyl-CoA and
malonyl-CoA. Another prominent pathway utilized by cells to obtain FAs is
exogenous FA uptake via transmembrane FA transporters including FA
Translocase (CD36). CD36 is a multifunctional glycoprotein, is primarily involved
in the binding and transportation of low-density lipoproteins and long-chain/ultralong-chain FAs. My research assessed the role of CD36 in CRC growth and
metastasis as well as the relationship between CD36 and FASN, particularly, the
aspect of this relationship when de novo lipid synthesis is inhibited using novel
FASN inhibitors.

FASN upregulation has been previously shown to contribute to primary
CRC growth and progression to metastasis. Chemical inhibition of FASN via a
novel FASN inhibitor TVB-3664, has shown significant promise in the treatment of
CRC in vitro by reducing CRC proliferation via a decrease is cellular respiration.
Interestingly, pre-clinical evaluation of this inhibitor in patient derived xenografts
(PDXs) in vivo suggests that high expression of FASN does not determine a
positive response to FASN-targeted therapy and only approximately 30% of PDXs
exhibit significant tumor reduction. These results suggest that there may be
alternative pathways which may contribute to FASN inhibition resistance.
CD36 has been studied in various diseases, including glioblastoma, breast,
ovarian, and oral carcinomas, where it has been found to significantly contribute
to disease progression and metastasis. However, CD36 has not yet been
thoroughly investigated in CRC, and has not been studied in relation to de novo
lipid synthesis. My studies show that CD36 is upregulated in CRC primary and
metastatic tumors and an increased expression level of CD36 is associated with
an increase in FA uptake. Furthermore, CD36 inhibition significantly decreases
proliferation of CRC established and primary cell lines in vitro, and knockdown of
CD36 reduces subcutaneous xenograft tumor growth in vivo. Most excitingly,
inhibition of FASN significantly and specifically upregulates CD36 expression, but
not other FA transporters, in human tissues, established and primary cell lines, and
genetically modified mice with heterozygous and homozygous deletion of FASN.
This upregulation of CD36 in the presence of FASN inhibition resulted in a CD36
specific increase in the uptake of exogenous FA analogues, further supporting the
role of CD36 as a potential compensatory mechanism to FASN-targeting therapy.
Additionally, inhibition of FASN and CD36 in combination resulted in an additive
effect on the reduction of CRC cell proliferation.
Late-stage metastatic CRC has a substantially lower rate of 5-year survival
compared to earlier stage disease. As aforementioned, in addition to primary CRC
cell survival and proliferation, CD36 was shown to be further upregulated in CRC
metastatic tissues. My studies demonstrate that CD36 promotes CRC cell invasion
and colony formation in vitro. Additionally, an increase in CD36 is associated with
more metastatic CRC cell lines and promotes metastasis of CRC cells in vivo.
Interestingly, CD36 expression is associated with matrix-metallopeptidase-28
(MMP28), the newest member of the matrix-metallopeptidase family of proteins.
MMP28 is involved in the degradation of the extracellular matrix (ECM), particularly
the disassembly of collagen fibers within cell-cell adhesions. MMP28 has been
suggested in the metastasis of various diseases including lung and gastric cancer.
MMP28 had not yet been investigated in CRC. Knockdown of CD36 decreases
MMP28 expression and increases the expression of e-cadherin, a critical protein
involved in cell-cell adherent junctions and whose loss is a well-known marker for
epithelial to mesenchymal transition (EMT) in various cancers. Furthermore,
knockdown of MMP28 is sufficient to significantly upregulate e-cadherin

expression suggesting that CD36 potentially regulates metastasis through early
EMT via the upregulation of MMP28 and loss of e-cadherin.
New therapeutic strategies in the treatment of CRC are urgently needed to
improve the survival rates of those patients with late-stage disease. Altered FA
metabolism is a common characteristic of many cancers including CRC. The
studies described here investigate the role of CD36 in CRC and upregulation of
CD36 as a potential compensation mechanism to FASN-targeted therapy which is
currently being tested in several clinical trials. The results of my studies
demonstrate that CD36 may present a viable target for treatment of both primary
and metastatic CRC. Furthermore, this study provides the rationale for targeting
CD36 in combination with FASN inhibitors and demonstrates that inhibition of
CD36 increases efficacy of FASN-targeted therapy via a reduction of the free-FA
pools available to CRC tumor cells. Further investigation into the mechanistic
functions of both CD36 and FASN in CRC as well as the contribution of CD36 to
CRC metastasis is needed to provide more efficacious treatment strategies of
CRC.
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CHAPTER 1. INTRODUCTION TO COLORECTAL CANCER, FATTY ACID
METABOLISM, FATTY ACID SYNTHASE, AND FATTY ACID TRANSLOCASE
1.1 Colorectal Cancer
Colorectal cancer (CRC) is the leading cause of non-smoking related
cancer deaths in the world, and the second leading cause of cancer related deaths,
with estimates of more than 145,000 new cases in the United States, including
more than 50,000 new deaths in 2020 [1, 2]. In 2018, diagnosed cases of CRC
were over 1.8 million worldwide, with over 800,000 deaths, a number which
accounted for almost 10% of all cancer related deaths in the world [3]. Current
models predict that CRC diagnoses will increase to over 2.5 million annually by
2035 [4]. As with many cancers, CRC has historically been viewed from the
perspective of a disease directly related to age. However, when looking at
epidemiological studies over the past 40 years, incidence rates for CRC in younger
age groups, those 20-49 years, has increased by over 47 % [5]. Patients within
high-risk demographics are encouraged to receive asymptomatic screening for
CRC as this has been shown to reduce mortality rates of the disease significantly
through both the removal of lesions prior to disease development as well as earlier
stage CRC diagnosis [6-9].
CRC, as with many of the oncogenic diseases, is heterogenous and can be
classified into several molecular sub-types [10-12]. The CRC Subtyping
Consortium, using six independent molecular classification systems, have
recognized four unique molecular subtypes of CRC which are: Microsatellite
Instability Immune (MII), Canonical, Metabolic, and Mesenchymal [10, 11, 13]. Of
these subtypes, the most prevalent at 37% is the Canonical, which is characterized
with marked wingless-related integration site (WNT) and MYC signaling activation.
CRCs typical of the Canonical subtype exhibit an initial loss of the adenomatous
polyposis coli (APC) gene followed by an activating mutation of the KRAS signaling
pathway in combination with the loss of tumor protein-53 (TP53) [13, 14]. Clinically,
nearly 40% of Canonical subtype CRC tumors are diagnosed at Stage III, however
this subtype represents the highest overall 5-year survival rate at nearly 80% [10].
This is followed by the Mesenchymal subtype at 23% of all CRCs, exhibiting
significant transforming growth factor beta (TGFβ) activation with stromal invasion,
angiogenesis, and can be both with and without prominent Wnt signaling. Tumors
of this subtype display pathologically serrated legions, with cells representing a
mesenchymal phenotype [15]. Cancer associated fibroblast (CAFs) with increased
TGF-β signaling profiles, as well as a prominent inflammatory microenvironment,
are also common of this sub-type [10, 13]. These are followed up by the MII
subtype at 14% and consisting of significant microsatellite instability and a
pertinent immune system activation. The MII subtype is specifically represented
pathologically by the presence of serrated polyp precursor legions, consisting of
high BRAF mutation rates, loss of tumor suppressor function and missed-match
repair (MMR) at the epigenetic level [16]. The combination of BRAF mutations and
1

MMR deficiency results in a hyper mutated genetic profile, with nearly a 20-fold
increase in mutation rate per 10^6 base pairs compared to microsatellite stable
tumors [10, 13, 16]. Lastly, the Metabolic subtype comprises 13% of all CRCs and
possesses increased metabolic dysregulation, particularly in the DNA repair,
glutaminolysis, lipogenesis and cell cycle pathways [10, 11, 13, 14]. More in-depth
investigation into the various subtypes of CRC and their unique molecular profiles
may increase treatment efficacy for CRC.
1.2 Treatment Strategies for CRC
As previously mentioned, CRC rates, although declining in those ages over
50, are increasing significantly in younger populations and CRC remains the
second most common cause of cancer related deaths in the world [5, 17]. Those
patients diagnosed with early stage CRC have nearly a 10 fold increase in 5 year
survival rate when compared to later stage disease with more distant metastases
[18, 19]. For those with earlier stage disease, the therapeutic approach is much
simpler, relatively speaking, than those with later, more advanced CRC.
A typical treatment strategy for those with stage 0-I CRC is surgical
excision of the cancerous lesion, typically contained within a polyp. In lesions not
contained within a polyp, or if the edge of the polyp still contains cancerous cells,
a partial colectomy may be recommended to remove the section of the colon with
disease [20, 21]. Those patients with more progressed disease, including some
stage II and stage III-IV CRC, surgical excision of the primary tumor and/or partial
colectomy is recommended in combination with adjuvant chemotherapy. Such
chemotherapeutic agents used in combination with surgical resection are nontargeted drugs and include 5-fluorouracil, leucovorin, oxaliplatin and capecitabine
[20, 22]. 5-fluorouracil (5FU) was one of the earliest chemotherapeutic anticancer
agents identified and is an antimetabolite, inhibiting the enzyme thymidylate
synthase, thus preventing the production of thymidine and consequently impeding
DNA synthesis and cell proliferation [23, 24]. 5FU is used across a wide range of
diseases including breast, skin, and head and neck cancers [25]. Although it has
seen some success in treating CRC, 5FU only produces significant response in
<20% of patients when used alone, and for that reason it is typically used in
combination with other therapeutics. [26, 27]. Combination of 5FU with leucovorin
as well as oxaliplatin have seen increases in treatment efficacy [28]. Leucovorin,
also known as folinic acid, significantly enhances the binding potential of 5FU with
thymidylate synthase, increasing patient response to 26-43%, depending on
treatment course [29]. Oxaliplatin is a third-generation platinum compound, with a
unique 1,2-diaminocyclohexane moiety [30]. Analogous with other platinum-based
therapeutics, oxaliplatin derived cytotoxicity is due to platinum induced DNA
crosslinks, typically between two guanines, or a guanine and adenine base pair,
resulting in inter- and intra-strand platinum-DNA adducts. Due to the 1,2diaminocyclohexane moiety however, these adducts are significantly bulky,
resulting in a more effective blocking of DNA-mismatch repair enzymes, and
consequently, an increased level of cytotoxicity when compared to other traditional
2

platinum-based therapies [30, 31]. Oxaliplatin alone produces relatively low
response rates in patients, approximately 20%, however, used in combination with
the 5FU and leucovorin, patient response rates significantly increase, to nearly
50%, accompanied by an increase in progression free survival [32-34]. Together,
this combined treatment regimen of oxaliplatin, 5FU and leucovorin is known as
the FOLFOX regimen. Other regimens consisting of multiple chemotherapeutics
agents in combination include FOXFIR, a mixture of 5FU and irinotecan, as well
as XELOX, an oxaliplatin and capecitabine mixture. The efficacy of these varying
regimens is comparable to each other [35]. Together these regimens remain the
standard approach for first-line treatment of CRC.
Due to the high mortality of advanced stage disease, there are several
ongoing efforts to establish effective targeted therapies for the treatment of CRC.
There has been emphasis on targeting the epithelial growth factor receptor (EGFR)
pathway including the protein EGFR, human epidermal growth factor receptors
(HERs), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and encoding
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). Within CRC patient
populations, those patients with aberrant EGFR upregulation comprise up to 77%
of the total CRC patients [36]. Furthermore, nearly 5% of CRC patients also exhibit
HER2 overexpression [37, 38]. Of the targeted therapies for EGFR, those most
prominent include the monoclonal antibody cetuximab and its fully humanized
derivative panitumumab [39, 40]. These therapeutics work to induce EGFR
degradation after biding to the receptor in its extracellular domain and have shown
great promise as first-line treatment for CRC [35, 39]. However, 10% of CRC
patients also exhibit oncogenic mutations in BRAF, which has been hypothesized
to contribute to anti-EGFR therapeutic resistance [41]. Current treatment of CRC
with mutant BRAF consists of using BRAF inhibitors, such as vemurafenib, in
combination with upstream, EGFR inhibitors such as cetuximab [42]. This
combination is necessary, as patients treated with BRAF inhibitors alone often see
no significant change in progression-free survival [35, 43, 44]. Additionally, it is
suggested that inhibition of EGFR can also upregulate the expression of HER2,
which, due do similar downstream RAS and PI3K signaling, can compensate for
EGFR inhibition [45]. To target HER2, a combinational treatment of trastuzumab
and pertuzumab, or trastuzumab and lapatinib are utilized [46, 47]. PI3K mutations
coincidentally can lead to downstream activation of AKT and resistance to EGFR
inhibition. Currently, several studies are investigating potential inhibitors to PI3K to
use in combination with EGFR targeted therapy, however much more
understanding is needed for effective inhibition of PI3K within the clinical setting
[35].
Another prominent pathway which has become the focus of targeted
intervention with metastatic CRC is the vascular endothelial growth factor (VEGF)
pathway, which is responsible for the regulation of angiogenesis [48]. Interactions
between VEGF-A and vascular endothelial growth fact receptor 2 (VEGFR-2)
result in the activation of downstream pathways including the previously mentioned
RAS/RAF/ERK/MAPK and PI3K/AKT pathways. Those patients with VEGF-A
3

gene amplification, while composing a relatively small number of total CRC
patients, have disease that is typically more aggressive and results in significantly
lower 5-year survival rates [49]. The monoclonal antibody bevacizumab is currently
the prominent antiangiogenic therapy targeting VEGF and still the only Food and
Drug Administration (FDA) approved first-line therapy which targets VEGF.
However, various new therapeutic agents are being developed and tested in phase
II and III clinical trials with some being approved for second-line treatment of CRC
[35, 50]. Due to the high complexity and varying pathway intersections involved in
the VEGF pathway, resistance to VEGF targeted therapy can frequently be
observed [35]. Strategies targeting VEGF in combination with other potential
pathways of compensation, such as the fibroblast growth factor (FGF) and c-Met
pathways as well as angiopoietin-2 signaling, have shown promise in pre-clinical
studies [51, 52]. However, in some early clinical trials, several strategies have
failed to yield significant results and more investigation is needed to improve
treatment modalities involving the targeting of VEGF [53].
More recently, advances in understanding of the immune checkpoint
pathway has led to development of multiple therapeutics which aim to enhance the
recognition and clearance of cancer cells by the immune system [54]. Two
prominent agents used to target the immune-checkpoint pathway in metastatic
CRC were pembrolizumab and nivolumab [35]. These treatments are both
monoclonal antibodies which target programmed cell-death protein 1 (PD-1) on
the tumor cell surface and which, through binding to programmed cell-death
protein 1-ligand (PDL-1), activates T-cell dysfunction and tolerance, resulting in an
escape by the tumor cell from the surveillance of the immune system [55-57]. Both
therapeutics earned FDA-approval after they displayed significant patient
response in those patients whose tumors exhibit high microsatellite stability (MSIH) [58, 59]. However, those patients with intact mismatch repair (MMR) showed
little to no response to these immune-checkpoint targeted therapies. Several other
potential treatments are currently under investigation and other therapeutic targets
within the immune-checkpoint pathway are also being explored with the hopes of
broadening the range of patients who respond well to this type of therapeutic
strategy.
1.3 CRC Treatment Efficacy
Screening for CRC, which typically consists of a colonoscopy and is the first
line of defense in the prevention of CRC, has drastically increased within the
United States in recent years [60]. Those patients between the ages of 50-75 years
have significantly increased their up-to-date screening rates since 2005, going
from 46.8% to 68.8% in 2018 [61, 62]. Consequently, the incidence and mortality
rates for CRC in these older populations have seen some decline since the
implementation and higher participation in early CRC screening [63]. Despite this
increase in screening and early CRC detection, late-stage CRC remains to be ever
problematic and with this, disease relapse and mortality rates continue to remain
high. Currently, only 36% of patients diagnosed with CRC have disease that has
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not yet spread to distant tissues while 20-25% percentage of patients are
diagnosed with late-stage metastatic CRC. [2, 64]. Those whose CRCs are
diagnosed at an early stage (Stage I-III) have a significantly higher 5-year survival
rate when compared to those diagnosed with much more progressed disease
(Stage IV), which has a 5-year survival rate of less than 14% [5, 8, 65] (Table 1.1).
Due to this significant reduction in survival of late-stage CRC, emphasis on
discovering new therapeutic strategies for late-stage CRC is necessary.
Achieving complete remission, or more specifically pathological complete
response (pCR), which is the complete absence of cancerous tissues via biopsy
or surgical resection, has been shown to significantly improve patient 5-year
survival. Those who do achieve pCR have an average 5-year survival rate of 83%
compared to those patients who do not, which have an average 5-year survival
rate of only 66% [66]. Those who are diagnosed with early stage, localized CRC
see almost 100% pCR after surgical resection [67]. Historically, those diagnosed
with later stage, invasive and/or metastasized CRC would likely only receive minor,
palliative primary surgical resection due to their increased tumor burden, which is
typically present with significant liver metastasis [67]. Due to advances in new
therapeutic approaches, patients with Stage II and III CRC can receive
neoadjuvant therapy; that is therapy which is administered pre-operatively to
reduce tumor burden to an operational size and can exhibit almost a 25% pCR rate
[68]. Those diagnosed with Stage IV disease, even if qualifying for curative
surgery, still exhibit a poor response rate [68]. This discrepancy between patient
groups can be contributed to the lack of pCR and the heterogeneity of metastatic
burden observed between different late stage CRC patients, resulting in a
significantly higher rate of disease recurrence [69].
Although several strategies have been employed to detect CRC recurrence
early, where it can be more effectively treated, disease recurrence remains high
[70]. Of all CRC patients treated, approximately 40% experience some sort of
recurrent disease [71]. More specifically, of all patients diagnosed with at least
potentially curable disease, up to 60% will relapse, often with more difficult-to-treat
metastatic disease [70]. The most critical period in which recurrence can occur is
3 years following completion of definitive care [72]. Strategies currently used to aid
in the early detection of recurrent CRC which have important clinical significance
include blood tests to monitor liver enzyme levels and regular imaging of both the
liver, the most common site of metastasis in CRC, and the lungs [70, 73, 74]. For
example, if monitored closely, up to 20% of recurrent liver metastasis can be
successfully surgically removed, with significant increases in patient survival [7577]. However, a large proportion of patients diagnosed with CRC could greatly
benefit in better preventative and detection strategies against recurrent CRC.
CRC patients diagnosed with local advanced, or late-stage disease are still
in need of more effective therapeutic strategies. More effective therapeutic targets
could improve definitive treatment of both primary and metastatic CRC as well as
assist in the prevention of disease recurrence. Recently, alternative pathways
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including that of cellar metabolism, specifically altered fatty-acid metabolism, have
been implicated in CRC progression and metastasis [78]. Dysregulation of lipid
metabolism is a hallmark of cancer; however further understanding of the
intricacies in this complex metabolic pathway is required to identify appropriate
therapeutic targets for CRC.
1.4 Fatty Acids and Fatty Acid Metabolism
1.4.1 Fatty Acid Structure and Distribution
Fatty acids (FAs) consist of a carboxylic acid which contain a long, aliphatic
side chain. This side chain of carbons can vary in number typically from 2-26 [79].
Categorically, FAs can be grouped in four groups based on the length of their
aliphatic side chain: short chain (2-6 carbon atoms), medium chain (8-12 carbon
atoms), long chain (14-18 carbon atoms), and very long chain (20-26 carbon
atoms) [79, 80]. FAs can be defined as saturated (SFA) or unsaturated (UFA)
where SFAs consist of molecules with no carbon-carbon double bonds, meaning
the entire molecule is completely saturated with hydrogen atoms aside from the
carboxyl group. UFAs contain at least one carbon-carbon double bond [81]. The
most common types of FAs found within mammals are the long-chain and verylong-chain FAs, which include palmitic and oleic acid [80].
Typically, FAs are not found in most organisms as stand-alone molecules,
but instead, they are most often in the forms of either cholesteryl esters,
phospholipids, or triglycerides. Cholesteryl esters are a FA bound to a cholesterol
molecule via an ester bond between the carboxyl group of the FA and the hydroxyl
group of the cholesterol. These molecules, when hydrolyzed at the ester bond,
release a free FA (FFA) and the cholesterol molecule for an energy source or
membrane and lipoprotein formation [82]. Phospholipids contain a hydrophilic
phosphate group bound to a hydrophobic region consisting of one or two FAs,
which are all bound to each other via a glycerol molecule [83]. These molecules
are then used for structural purposes, specifically membrane synthesis throughout
the cell. Triglycerides (TGs) are esters formed by a glycerol molecule and three
FAs. TGs are the primary component of fat within the body [81]. As with FAs alone,
TGs can be considered saturated or unsaturated. The FA chains contained within
the TG can all vary in length, but typically consist of either 16, 18, or 20 carbon
atoms. Primarily, TGs are metabolized by a member of the pancreatic lipase family
of enzymes, which hydrolyzes the ester bond within the TG, releasing the three
FFAs and the glycerol molecule in a process known as lipolysis [81]. These FAs
can then be readily absorbed in the intestine and utilized by the cells [84].
1.4.2 Fatty Acids as Building Blocks of Cellular Membranes
The most abundant and fundamental building block of all cellular
membranes are phospholipids [85]. These critical components account for 50-60%
of the total membrane lipid composition [85]. Phospholipids, because they contain
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both hydrophilic and hydrophobic properties (also known as amphiphilic), can form
lipid bilayers [86]. The FA component of these phospholipids form the hydrophobic
tails, which due to entropy, cause the spontaneous formation of the bi-lipid layer in
aqueous solutions [85]. Typically, the phospholipid consists of two FA tails, one of
which is unsaturated with one or more double bonds, and the other is saturated,
with no double bonds present [83, 87]. This heterogeneity allows the numerous FA
tails of the phospholipids to arrange in such a way spatially that they are tightly
packed yet still fluid relative to each other [87]. The fluidity of the bi-lipid layers is
critical to the normal function of various proteins which are embedded within the
membrane as well as the diffusion of other biomolecules [88]. Phospholipid
molecules can diffuse laterally within the same monolayer, as well as flip-flop
across monolayers, although the flip-flop is much less common [87]. To facilitate
the movement of new phospholipid molecules across the two monolayers for the
purpose of new membrane synthesis and membrane repair, the cell utilizes
phospholipid translocator enzymes to catalyze the process [87]. The degree of
fluidity of the membrane can also vary based on the variations in unsaturation of
the FA tails. More unsaturated tails, containing more double bonds, allow for a
more fluid membrane due to the spatial requirement of the double bonds and thus
the less densely packed lipid molecules [87]. The unique dynamics of the
phospholipid bilayer allow the cellular membranes to be incredibly diverse while
serving as a strong barrier for the entire cell from its external environment, as well
as separating the various compartmental organelles and the nucleus within the cell
[85, 86].
Alongside phospholipids, FAs also contribute to the formation of numerous
other types of lipids found within cellular membranes including sterols (primarily
cholesterol), and sphingolipids [89]. Sterols, with cholesterol being the most
prominent type in mammalian cells, comprise nearly 30% of the cellular membrane
[90]. Cholesterol can be synthesized de novo or transported and internalized in the
form of low-density lipoproteins (LDLs) [91].Cholesterol contributes significantly to
the structural integrity of cell membranes as well as helps mediate membrane
fluidity [92, 93]. Sphingolipids are lipids which are composed of a spingoid base
backbone, a backbone comprised of aliphatic amino alcohols, the most common
being sphingosine, attached to a FA via an amide bond [94]. Sphingolipids
contribute structurally to cell membranes as well as serve as cell signaling
molecules [95]. Sphingolipids can frequently associate with cholesterol within the
cell membrane to form lipid rafts [96]. These relatively more-dense areas of the
cell membrane can contain various signaling proteins and contribute to overall
membrane fluidity [97, 98]. It is proposed that lipid rafts facilitate cell signaling by
providing spatial arrangements of various proteins, allowing for more precise
protein-protein interactions and thus contributing to numerous signaling cascades
[99].
1.4.3 Fatty Acids as Signaling Molecules
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Furthermore, aside from membrane formation, FAs can be utilized as lipid
signaling molecules. Such molecules include prostaglandins, which are
synthesized using arachidonic acid (AA), the 20-carbon unsaturated fatty-acid, and
are key mediators of inflammatory responses to infection or injury [100, 101]. Other
signaling molecules synthesized from AA, also known as eicosanoids, include
thromboxane’s and leukotrienes, which are responsible for blood clotting and
immune function regulation, respectively [102].
As previously mentioned, sphingolipids, aside from facilitating cell signaling
through lipid rafts, can themselves also serve as signaling molecules within the
cell [95, 99]. Sphingolipids, particularly their metabolites ceramide, sphingosine,
and sphingosine-1-phosphate, contribute to the signaling of cellular differentiation,
cellular apoptosis and proliferation [95]. Ceramide, produced by the hydrolysis of
sphingomyelin by sphingomyelinase, is typically the primary secondary messenger
in sphingolipid dependent cell signaling [103]. Ceramide has been shown to be
directly related to cellular apoptosis [104]. Conversely, sphingomyelin synthase
facilitates the synthesis of sphingomyelin from ceramide, together forming the
sphingomyelin cycle [105]. The phosphorylation of sphingosine by the two kinases
sphingosine kinase 1 and 2 (SPHK1 and SPHK2) yields sphingosine-1-phosphate
(S1P) [106]. S1P is involved in various cell signaling pathways including cell growth
and suppression of apoptosis [107, 108]. Interestingly, S1P directly mediates
apoptosis suppression through the inhibition of ceramide signaling, thus creating
a well-regulated balance in which intracellular levels of ceramide and S1P
contribute to overall cell fate [108].
In addition to the aforementioned FA derivatives involved in cell signaling,
FFAs themselves can be utilized as cell signaling molecules [109]. FFAs can
stimulate the transcription of numerous genes involved in various metabolic
pathways. SFAs can stimulate genes within the sterol-regulatory element binding
protein 1 (SREBP1) pathway, which in turn is responsible for the synthesis of other
FAs and cholesterol [110, 111]. UFAs can however stimulate fatty-acid oxidation
and in turn prevent further production of new UFAs [112].
1.4.4 Fatty Acids as An Energy Source
As previously mentioned, FAs are an important source of energy regarding
cellular metabolism [79, 80, 102]. FAs have nearly twice the yield of energy
compared to carbohydrates [113]. The key element of FAs which make them a
prospective energy source for cells is their long aliphatic side chain. When a FFA
is present within the cell, the primary method in which they are utilized for energy
is FA beta-oxidation (FA β-oxidation), which describes the formation of acetylcoenzyme-A (acetyl-CoA) molecules via the breakdown of long chain FAs [79,
114-116].
For a FA to first enter the FA β-oxidation pathway, a coenzyme-A (CoA)
group is added to the FA via a thioester bond resulting in a fatty acyl-CoA molecule.
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This reaction is also known as FA activation, and is catalyzed by a cytosolic acylCoA synthase(ACS) enzyme [117]. The specific acyl-CoA synthase used is
dependent on the length of the FA. FA β-oxidation occurs within the mitochondria,
however long chain FAs and fatty acyl-CoA molecules cannot freely translocate
across the mitochondrial inner and outer membranes [79, 114, 116]. To overcome
this limitation, a specific transport mechanism, the carnitine shuttle system, is
utilized. A carnitine molecule is added to the newly formed fatty acyl-CoA molecule
by carnitine palmitoyl transferase 1 (CPT1) on the surface of the outer
mitochondrial membrane. The resulting fatty acylcarnitine can then be transported
across the outer mitochondrial membrane and into the intramembranous space
between the inner and out membranes [114, 116]. To then cross the inner
mitochondrial membrane, the fatty acylcarnitine is transported via acylcarnitine
translocases. Once across the inner mitochondrial membrane, carnitine palmitoyl
transferase 1 (CPT2) removes the carnitine molecule from the fatty-acyl-CoA, and
the carnitine is shuttled back across the inner and outer membranes to be recycled
for further FA transport [114, 116]. Of these phases, the transfer of carnitine to the
fatty-acyl-CoA by CPT1 is the rate limiting step, with malonyl-CoA acting as an
inhibitor of CPT1, reducing FA β-oxidation [114]. In periods of fasting, malonylCoA levels fall, favoring FA transport across the mitochondrial membrane and
increased beta oxidation [80, 114].
Once the fatty acyl CoA is completely inside the mitochondria, FA βoxidation can occur. The first step in FA β-oxidation is the removal of two hydrogen
molecules from the beta and gamma carbons of the acyl-CoA by acyl CoA
dehydrogenase and an flavin adenine dinucleotide (FAD) molecule [114-117]. This
results in the production of one FADH2 molecule and a 2-trans-enoyl CoA. The 2trans-enoyl CoA is then hydrated across the same two carbons by enoyl-CoA
hydratase, resulting in an L-β-hydroxyacyl CoA. The resulting hydroxyl group
within the L-β-hydroxyacyl CoA is oxidized by 3-hydroxyacyl-CoA dehydrogenase
and a nicotinamide adenine dinucleotide (NAD+) molecule resulting in β-ketoacyl
CoA and an NADH [114-117]. Lastly, the β-ketoacyl CoA is cleaved by a thiol group
of another, independent CoA molecule, by β-ketothiolase between the beta and
gamma carbons. This results in a single acetyl-CoA molecule consisting of the
alpha and beta carbons of the original fatty acyl-CoA, and a new fatty acyl-CoA
molecule that is two carbons shorter [114-117]. This process then repeats itself
until the final four carbons from the original acyl-CoA chain are cleaved into two
acetyl-CoA molecules [114-117]. Therefore, for each cycle of FA β-oxidation, one
acetyl-CoA molecule is produced along with one FADH2 and one NADH. The
acetyl-CoA can then enter the tricarboxylic acid cycle (TCA) where it is oxidized to
form three more NADH molecules as well as one more FADH2 and a single
adenosine triphosphate (ATP), which is the primary molecule used for energy
within the cell. The NADH and FADH2 molecules are then further utilized within the
electron transport chain, where each NADH molecule can generate 3 ATP and
each FADH2 molecule can generate 2 ATP [118].
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1.5 Fatty Acids Acquisition: Synthesis vs. Uptake of Dietary FAs
There are multiple pathways in which cells can acquire FAs (Figure 1.1).
When FAs are released from fat tissue, more specifically from triglycerides via
lipolysis as described previously, the FFAs are then transported throughout the
circulatory system, typically chaperoned by albumin [119]. In this form, FAs can
then be incorporated into most cell types within the body via specific FA
transporters. Such FA transport molecules include the FA transport family of
proteins (FATPs), FA binding proteins (FABPs), and FA translocase (CD36) [120].
These FFAs are then typically utilized as an energy source via FA beta oxidation
but can also be used for a variety of purposes as mentioned above.
Alternatively, cells may synthesize FAs de novo through the de novo FA
synthesis pathway. This pathway describes the method in which acetyl-CoA and
malonyl-CoA, are converted into long-chain FAs [121]. This process involves the
critical enzymes acetyl-CoA carboxylase (ACC) which carboxylates acetyl-CoA to
form malonyl-CoA, and FA synthase (FASN), which synthesizes long chain FAs
from malonyl-CoA [122]. FAs synthesized via de novo lipid synthesis are then
utilized for both membrane construction and as an energy source.
Both pathways in which FAs can be obtained or synthesized are the major
contributors to FA metabolism and are well regulated. The sterol regulatory
element-binding proteins (SREBPs) are important transcription factors in the
regulation of genes involved in both de novo lipogenesis and the uptake of
exogenous cholesterol [123, 124]. Such genes involved in the SREBP regulation
of de novo lipid synthesis include citrate carrier protein solute carrier family 25
member 1 (SLC25A1), which specifically contributes to glucose-mediated lipid
synthesis by shuttling citrate from inside the mitochondria across the mitochondrial
membrane and into the cytosol where it serves as a precursor to de novo FA and
cholesterol synthesis [125, 126]. In relation to the regulation of exogenous FA
uptake and utilization, the peroxisome proliferator-activated receptor (PPAR)
family of proteins have been shown to be involved [127]. In liver and intestinal
tissues, increased activation of PPARα increases transcription of FATPs and
ACSs, which are mediators of FA transport and activation [127]. Additionally,
PPARγ activates the transcription of FATPs and ACS in adipose tissues,
suggesting that increases in exogenous FA uptake in dependent on tissues
specific signaling cascades[127]. The regulation of other important proteins
involved in de novo lipid synthesis and exogenous FA uptake, such as FASN and
CD36, is still being investigated and much work is left to be done.
1.6 Fatty Acid Metabolism Dysregulation and Cancer
Altered FA metabolism has long been established as a hallmark of cancer
[128-130]. Cancer cells are typically rapidly dividing and require significantly larger
amount of energy to sustain their growth. FAs, as both an energy source and a
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primary component of lipid membranes, which are required for newly dividing cells,
are a prime resource for cancer cells [123, 131]. Specifically, cancer cells have
been shown to utilize FAs to sustain proliferation and meet their energy demands
in times of high metabolic stress [122].
Increased levels of FAs and FA metabolism have been shown to promote
cell proliferation and disease progression in multiple cancers [78, 123, 132]. For
example, ATP citrate lyase (ACLY) is an important enzyme linked to glucose
metabolism and is involved in lipid synthesis through the conversion of citrate to
oxaloacetic acid and acetyl-CoA [133]. ACLY promotes the growth of lung
carcinoma cells in vitro and is a poor prognostic factor for patients with non-small
cell lung cancer [134, 135]. Furthermore, ACLY has also been implicated in the
tumor progression and as a poor prognostic factor in other cancers including
prostate, breast, bladder, and hepatocellular carcinoma [136-139]. Conversely,
proteins involved in the uptake of exogenous FAs have also been implicated in the
promotion of cancer [123]. The low-density lipoprotein receptor (LDLR) family of
proteins are responsible for the binding of exogenous LDLs and internalizing them
[91]. These receptors have been shown to be upregulated and significantly
contribute to tumor growth in glioblastoma [140]. Additionally, various members of
the FATPs and FABPs have been implicated in cancer progression, including
FABP4 in the promotion of breast cancer tumor proliferation and FATP4 in the
tumorigenesis and tumor progression of renal cell carcinoma [141, 142].
Other proteins have been shown to be involved the dysregulation of FA
metabolism in numerous diseases via the regulation of de novo lipid synthesis and
exogenous FA transport [123, 124, 132]. The SREBP family of proteins have been
shown to promote tumorigenesis, cell proliferation, and disease progression in
numerous cancers including glioblastoma, renal cell carcinoma, hepatocellular
carcinoma, hepatocellular carcinoma, prostate cancer, and CRC [143-146]. For
example, SREBP1 and SREBP2 were found to contribute to CRC glycolysis, FA
oxidation, and mitochondrial respiration and inhibiting both transcription factors
lead to a reduction in CRC cell proliferation [143]. Additionally, SREBP-1
upregulates LDLR signaling in glioblastoma [140]. However, there is some
controversy over the regulation of some FA metabolism proteins and cancer
progression, including that of PPAR regulation of FABPs. PPARα induced
expression of FABPs has been shown to both correlate with hepatocellular
carcinoma progression as well as have antitumorigenic effects [147, 148]. Further
understanding of the intricacies of FA metabolism regulation is required if new
therapeutic targets are to be properly identified.
In CRC, aberrant FA metabolism and increased levels of FAs have been
shown to promote CRC cell proliferation and disease progression [78].
Understanding mechanisms of dysregulated lipid metabolism and identifying
potential therapeutic targets within this pathway are potential strategies in
developing new therapeutic approaches for CRC. Interestingly, no work has
previously looked at the relationship of de novo lipid synthesis with exogenous FA
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uptake in CRC. CD36 is suggested to be involved in the progression of
glioblastoma, oral, ovarian, and prostate cancer while FASN has been implicated
in the promotion of CRC progression and metastasis [149-154], but the crosstalk
between these two proteins has not been described before. My work provides new
insight on the interconnection of these proteins during CRC progression and
metastasis and provides the rationale for developing new therapeutic strategies
targeting lipid metabolism in CRC.
1.7 FASN Structure and Regulation
FASN not a single enzyme, but in fact is a homodimer of two identical
polypeptide subunits, with each subunit containing an entire system of seven
enzymatic domains [155]. The enzyme contains three catalytic domains within the
N-terminus which are the ketoacyl synthase (KS) domain, the
malonyl/acetyltransferase (MAT) domain, and the dehydrase (DH) domain [155,
156]. The enzyme also consists of four separate domains in the C-terminus: the
enoyl reductase (ER), ketoacyl reductase (KR), acyl carrier protein (ACP) and the
thioesterase (TE) domains [155, 156]. Those enzymes at the N-terminal domain
are primarily responsible for the binding of substrates, which are acetyl-Coa and
malonyl-CoA. Those enzymes contained within the C-terminal domain are
responsible of reduction of the newly forming FA precursor, and ultimately release
of palmitate by the TE domain [156]. The ACP domain, which contains a prosthetic
4’-phosphopantetheine group, is responsible for the shuttling of all intermediates
throughout the FA synthesis process [157, 158]. There are currently multiple
models which predict the exact molecular structure of FASN. The current model of
FASN arrangement suggests that the two identical subunits are arranged
antiparallel, thus resulting in two active centers that are composed of the KS
domain, responsible for chain elongation, and the ACP, KR, and ER domains,
which are responsible for reduction. Therefore it is understood that FASN has two
active centers that can act independently of each other and operate simultaneously
[159].
It has previously been shown that FASN is strictly regulated by nutritional
and hormonal stimuli [160, 161]. It has been shown that high-carbohydrate diets
and increased blood insulin levels significantly upregulate FASN expression [162].
Regulation of FASN is not known to be due to covalent modification or due to
allosteric regulation. Instead, the regulation of FASN is primarily at the
transcriptional level [163]. FASN contains a 147-base pair (bp) region within its 5’
promoter in which a sterol regulatory element (SRE), a specific sequence of 5′ATCACCCCAC-3′ in which SREBPs can bind, is present at the150bp [164-167].
Along with this SRE, there are two regions containing an enhancer-box (E-box),
one at the 65bp and another more upstream at the 332bp [165]. E-boxes are
specific DNA sequences of CANNG which are recognized as binding sites for
various transcription factors. The transcription factors specifically responsible for
transcriptional regulation are upstream stimulatory factors (USFs) and SREBP-1a
[163-166]. USFs are members of the helix-loop-helix leucine zipper family of
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transcription factors [161]. USF1-2 heterodimers binding to the 65bp E-box is
necessary for insulin mediated FASN transcription however further binding of
USF1-2 to the 332bp E-box confers full activation of the gene [166]. Additionally,
SREBP-1a, through interactions with the SRE at the 150bp and in combination
with USF binding the two E-boxes, can further activate FASN transcription [165].
1.8 FASN Function
FASN is a key enzyme of de novo FA synthesis. FASN is crucial for the
synthesis of palmitate, the 16 carbon long-chain saturated FA from both acetylCoA and malonyl-CoA [155]. The synthesis of FAs via FASN is an exceptionally
complicated process, which involves each of the seven enzymatic domains of the
protein [155]. As mentioned previously, each monomer of the homodimer which
comprises FASN can function independently and simultaneously to synthesize
FAs [159]. Within a single monomer, the synthesis begins with the transfer of
acetate from acetyl-CoA to the KS domain along with the transfer of malonate from
malonyl-CoA to ACP by the MAT domain [155, 168]. The KS domain then
catalyzes the condensation of acetate and malonate to form acetoacetyl-ACP and
CO2 [155, 169]. Next, the acetoacetyl group is reduced by the KR domain to form
B-hydroxyacyl-ACP which requires an NADPH molecule. The DH domain then
catalyzes the dehydration of β-hydroxyacyl-ACP followed by another reduction by
the ER domain, forming a saturated four carbon FA attached to ACP [155, 157,
168, 169]. The KS domain then transfer the saturated fatty acyl from the ACP to
itself, resulting in a net gain of two carbons to the acyl chain for each cycle of
elongation. The now free ACP can renter the cycle, and after a total of six cycles,
a single ACP attached to a palmitate (C:16) is synthesized. The final domain, the
TE domain, the hydrolyzed the synthesized palmitate from the ACP, resulting in a
free palmitic acid [155, 157, 158, 168, 169].
Typically, FASN is found within the normal tissues of the liver and adipose,
where more lipogenesis occurs and is expressed at relatively lower levels in most
other normal tissues [159]. FASN can mediate energy homeostasis by
synthesizing lipids for the purpose of storage during periods of excess food intake
[170]. Furthermore, FASN can play an important role in membrane synthesis and
homeostasis and thus cell division via the utilization of palmitate to form very-longchain FAs, which can then be utilized for the formation of glycolipids and
sphingolipids as well as ceramides [170, 171].
Overall, FASN functions as an important mediator of FA metabolism within
the cell. By being a sensor to nutrient availability as well as an intermediate
contributor of membrane synthesis, FASN is significant within several crucial
pathways within a cell. Most importantly, FASN is an incredibly complex protein,
consisting of several unique enzymatic domains responsible for the synthesis of
FAs, making it a critical component of de novo FA synthesis. However, more
research is needed to further understand the diverse set of downstream signaling
pathways in relation to FASN-mediated de novo FA synthesis.
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1.9 FASN in CRC
Due to FASN’s critical role in de novo lipid synthesis in various tissues and
since altered FA metabolism is a well-established hallmark of cancer and is
observed in CRC, it was possible that FASN may have a role in the development
and progression of CRC [128-130]. Indeed, it has been shown that FASN
expression is elevated in CRC primary tumors and FASN expression is further
elevated in later stage disease and is a poor prognostic factor for patient survival
[153, 172]. More specifically, it has been shown that inhibition of FASN reduces
signaling associated with CD44, a cell surface protein involved in several pathways
including cell proliferation, migration and angiogenesis and has been implicated in
tumor progression and metastasis of multiple cancers, including CRC [153, 173].
Additionally, FASN was found to directly play a role in the maintenance of energy
homeostasis in CRC by increasing de novo lipid oxidation [154]. Also, FASN has
been implicated in the inhibition of autophagy in CRC through the accumulation of
p62, a substrate which is degraded during autophagy, although more investigation
is needed to delineate a specific mechanism [154]. Furthermore, FASN has been
shown to play an important role in CRC cell proliferation and survival in vitro via
the regulation of the AMP-activated protein kinase (AMPK)/ mammalian target of
rapamycin (mTOR) pathway [172]. Together, the current literature supports the
suggestion that FASN enhances CRC progression through increased FA
metabolism, cellular respiration and alteration of oncogenic signaling.
1.9.1 FASN as a Chemotherapeutic Target in CRC
The striking upregulation of FASN in CRC and its role in CRC progression
and poor prognosis make it a desirable target for therapeutic intervention. Multiple
chemical inhibitors of FASN have been developed, including C75 and cerulenin
[174-177]. C75 interacts with the KS domain of FASN and is a weak irreversible
inhibitor [176]. Cerulenin is an antibiotic which was one of the earliest discovered
inhibitors of FASN and interacts with the KS domain [177, 178]. Although C75 and
cerulenin both showed promising anti-tumorigenic effects and increased cell death
in vitro, both drugs induced significant side effects including weight loss and
reduced nutrient consumption in mice [179]. These complications prevented these
drugs from becoming more prominent therapeutic targets for CRC patients.
Another drug, which is a potent FASN inhibitor, is orlistat [180]. Orlistat is FDAapproved for the treatment of obesity and has shown antiproliferative properties
against prostate cancer cell lines in vitro [180]. However, antitumorigenic effects
of orlistat were less significant in xenograft models, and the drug is poorly soluble
and does not easily cross the cell membrane, making it a less feasible therapeutic
for CRC [181]. The repeated failures of multiple therapeutics emphasize the need
for novel therapeutics with the potential to successfully and safely target FASN.
One novel chemical inhibitor which has been developed to target FASN and has
shown promise is TVB.
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TVB compound have been developed by 3V-Biosciences, now known as
Sagimet Biosciences, and is a potent reversible inhibitor of FASN [182]. TVB has
a lower molecular weight and increased solubility compared to that of other FASN
inhibitors mentioned above [183]. TVB acts through the reversible binding to the
KR domain of FASN, inhibiting the first reduction of the acetoacetyl-ACP during
FA synthesis [184].There are several analogs of TVB: TVB-2640 is used for clinical
trials and their analogs TVB-3166 and TVB-3664 are used for pre-clinical studies
in vitro and in vivo [185]. TVB-3166 has shown anticancer effects on oral
squamous cell carcinoma cell lines as well as cell lines derived from lung, ovarian,
breast, pancreatic, prostate, and hematopoietic cancers [184, 186]. In relation to
CRC, TVB-3664 has demonstrated impressive anti-tumor activity and significant
reduction of CRC established and primary cell line proliferation in vitro [185].
Increased expression of FASN was indicative of increased sensitivity to TVB-3664
in vitro [185]. Furthermore, the effect of TVB-3664 on CRC tumor growth in vivo
was studied using patient derived xenografts (PDXs). PDX models are useful tools
for preclinical drug evaluations because PDX tumors retain much of their parental
host properties when implanted into mice, including their microenvironment and
heterogeneity [187-190]. When various CRC PDX models, which tested positive
for FASN expression, were analyzed for TVB sensitivity in vivo, 30% of PDXs
responded positively, with up to 50% reduction in tumor weight [185]. However,
40% of PDXs treated had little to no response to TVB-3664 treatment, and two of
the PDX models exhibited a negative response to TVB-3664 [185]. This then
suggests that FASN expression alone is not sufficient to predict sensitivity to TVB
treatment in vivo.
To further emphasize the clinical significance of targeting de novo FA
synthesis using TVB, currently there are multiple Phase I/II clinical trials open using
TVB analogs [191-193]. These include studies in lung and breast cancer as well
as CRC [191-193]. Currently, TVB is in a Phase I clinical trial for CRC and it is yet
to be seen how patient tumors respond to treatment [192]. However, with preclinical indications that not all patients will respond positively to TVB treatment
alone, an investigation into potential alternative pathways which may contribute to
TVB resistance is needed [185]. Due to FASN’s critical role in de novo FA
synthesis and FA metabolism, other proteins involved in FA metabolism maybe be
suitable targets, such as those involved in the uptake of exogenous FAs, including
CD36.
1.10 CD36 Structure and Regulation
CD36 is a 53kd transmembrane protein, which contains two intracellular
domains, one at both the C and N-terminus, as well as two transmembrane
domains, and one extracellular domain [194]. The N-terminal half of the protein is
where the binding domains of CD36 exist. These binding domains are responsible
for the binding of multiple ligands including thrombospondin, oxidized LDLs (oxLDLs), and long chain and very long chain FAs [194, 195]. The extracellular
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domain facilitates lipid binding, and the C-terminus can associate with Src-tyrosine
kinases (Figure 1.2).
The exact full structure of CD36 has yet to be fully delineated; however,
several models have predicted the structure of CD36 with greater than 90%
confidence [196, 197]. There is particular emphasis on modeling and identifying
the exact structures involved in the FA binding pocket of CD36. A lysine residue at
the 164 amino acid position (Lys-164) was found to be critical for FA binding [198].
It is suggested that this binding to Lys-164 by the FA further confers a
conformational change within CD36 that facilitates cellular uptake [194, 199].
CD36 contains a central tunnel which traverses the entire length of the
protein [194]. Models show that the FA binding pocket contains a groove which
leads directly into the central tunnel of CD36 [194]. It is suggested that FA binding
to Lys-164 in the binding pocket could displace a glutamate 335 residue at the top
of the tunnel, allowing the FA access to the tunnel [198]. It was also discovered
that the tunnel has an exterior entry point on the surface of CD36, separate from
that of the FA binding pocket [198]. Free access to the tunnel by a FA may be
restricted due to an acetylated Lys-231 residue at the tunnel entrance [198].
However, further studies beyond modeling are required to fully realize CD36’s
structure, particularly those structures of the FA binding pocket and the central
tunnel.
The promoter region of CD36 contains peroxisome proliferator-activated
receptor (PPAR) response elements (PPREs), and therefore PPARγ can regulate
the mRNA transcription after binding to its ligands, of which include ox-LDLs and
some prostaglandins [200]. Specifically, a positive feedback loop has been
described in macrophages, where ox-LDLs absorbed by CD36 further active PPAR
signaling through the mitogen-activated protein kinase (MAPK) signaling cascade,
and thus increasing transcription of CD36, and in return further increasing ox-LDL
uptake, leading to foam cell formation [201]. In addition to the PPREs, an
interferon-γ-activated sequence (GAS) was also identified in the promoter region
of CD36, of which can be bound by signal transducer and activator of transcription
3 (STAT3). Binding of STAT3 to this GAS region in response to several Janus
kinase (JAK) ligands, such as epidermal growth factor (EGF), and promotes CD36
transcription [202].
CD36 is heavily post-translationally modified with modifications including
phosphorylation, glycosylation, palmitoylation, acetylation and ubiquitination [194].
These modifications create a protein with a mass of approximately 88kD
[203].Trafficking of the protein and membrane localization is heavily regulated.
Specifically, there are two palmitoylation sites at each of the termini which are
necessary for membrane localization. Furthermore, CD36 consists of several
disulfide bridges within the carboxyl terminal half, which are also important for
membrane association [194]. Moreover, CD36 contains nine extracellular sites
where it is glycosylated (asparagine 79, 102, 134, 205, 220, 235, 247, 321, and
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417) [204]. Glycosylation at each of these sites was shown to be critical for overall
protein folding as well as cellular trafficking of the protein to the cell membrane
[204].
CD36 may also be regulated based on fatty acid uptake and diet [194, 205].
A separate lysine residue within the FA binding pocket, Lys-166, was found to be
acetylated which increases the hydrophobicity of the pocket, which is suggested
in the regulation of FA access to the binding pocket or assist in the orientation of
the FA once within the pocket [194]. Furthermore, CD36 may be nutritionally
regulated via ubiquitination at two lysine residues within the C-terminus, which is
upregulated with increased FFA availability and decreased with insulin treatment,
suggesting a negative feedback loop during increased FFA availability [205].
1.11 CD36 Function
CD36 is expressed in various tissues throughout the body and is enriched
in tissues of the circulatory system, immune cells, and particularly expressed in
adipose tissues [206]. CD36 is also basally expressed at relatively lower levels in
tissues of the digestive tract, particularly the small intestine and colon [206]. CD36
is a multifunctional glycoprotein and is a receptor for several ligands including
thrombospondin (TSP-1), ox-LDLs and FAs and based on the tissues where CD36
is expressed, its function may be significantly different [207].
CD36 was first described as a receptor for TSP-1 and binding of TSP-1 by
CD36 has been shown to regulate several cellular functions including the negative
regulation of angiogenesis in ovarian tissues [208]. Furthermore, CD36 has been
shown to facilitate the interaction between Src-homology-2-domain-containing
protein tyrosine phosphatase (SHP-1) with vascular endothelial growth factor
receptor 2 (VEGFR2) and, thus, reducing vascular endothelia growth factor
signaling (VEGF) in endothelial cells [209]. CD36 binding to TSP-1 on the surface
of platelets results in a hyperactive platelet state and promotes thrombosis [210].
CD36 can also facilitate intracellular signaling through other Src-tyrosine kinases
in pathways including inflammation and atherosclerosis [210].
Aside from thrombospondin binding, more recently it has become well
established that one of the major functions of CD36 is the binding and uptake of
ox-LDLs and long-chain and very-long chain FAs [194, 211-213]. Interestingly, it
was found that both FAs and ox-LDLs share the same binding position within the
FA binding pocket, which include both the Lys-164 and Lys-166 residues [214].
The major areas of study delineating CD36’s function in the binding of ox-LDLs
involve its role in the progression of atherosclerosis [215]. Ox-LDLs are now
recognized as a marker for inflammation and atherosclerosis, and CD36 mediated
uptake of ox-LDLs has been directly linked to chronic inflammation and
atherosclerosis [215]. More specifically, interactions between CD36 and ox-LDL
can result in the formation of CD36-toll-like-receptor (CD36-TLR) complexes,
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which activate nuclear factor kB (NF-kB) signaling and increased inflammation
[216].
CD36 is highly expressed in adipose tissues and regulates lipid storage and
lipolysis and in the presence of insulin, facilitates uptake of FAs [203, 215]. It was
shown that the carboxyl group of a FA interacts directly with the Lys-164 at the
entry position to the FA binding pocket, suggesting the Lys-164 aides in the proper
positioning of the FA, orienting the long acyl chain of the FA so that it enters the
pocket first [198]. Although the FA binding pocket is critical for the binding of FAs,
it alone is not sufficient for full transfer of the FA into the cell. The central tunnel,
which traverses the entire length of the protein, is connected to the FA binding
pocket via a groove and is also critical for FA uptake as it is through this tunnel
that FAs move through CD36 and to the cell membrane [194]. FAs bound and
transported across the cell membrane by CD36 can then be used for a variety of
purposes as described above, include as an energy source or substrates for
membrane synthesis [215].
1.12 CD36 in Cancer
Due to the important role CD36 plays in the uptake of extracellular FAs, and
the fact that dysregulated FA metabolism is a hallmark of cancer, it is possible that
CD36 may play a role in the progression of CRC. CD36 has been shown to
contribute to the progression and metastasis of hepatocellular and oral carcinoma,
as well as glioblastoma, prostate, cervical, breast and ovarian cancers [149-152,
217-221].
In hepatocellular carcinoma (HCC), CD36 was shown to be significantly
upregulated in patient tissues and established HCC cell lines [221, 222].
Furthermore, CD36 expression increased HCC cell proliferation, migration, and
invasion in vitro as well as the promotion of tumor growth and metastasis in vivo
[221]. Additionally, it was shown that CD36 promotes the progression of HCC by
activating glycolysis through the upregulation of the Src/PI3K/AKT/mTOR
signaling pathway [221]. Furthermore, it has also been shown that CD36
contributes significantly to epithelial to mesenchymal transition (EMT) in HCC via
CD36 mediated FA uptake [222]. It was suggested that CD36 promotes this EMT
in HCC through increased Wnt-TGFβ signaling; however more investigation is
needed to fully discern the mechanisms behind CD36 -driven EMT [222].
As mentioned, aside from HCC, CD36 has also been shown to promote
glioblastoma (GBM) progression [149]. Specifically, CD36 is highly upregulated in
GBM cells and is enriched further in GBM cancer stem cells (CSCs) [149].
Furthermore, reduced expression of CD36 significantly inhibited the self-renewal
and tumorigenic properties of GBM CSCs. Additionally, treatment of GBM CSCs
with ox-LDLS enhanced cell proliferation [149]. Lastly, the expression of CD36 in
GBM patients correlated with a poor prognosis [149]. However, exact mechanistic
pathways in which CD36 enhances GBM progression have yet to be delineated.
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CD36 has also been shown to promote the progression of ovarian, cervical
and breast cancers [151, 218-220]. In ovarian cancer, it was shown that CD36
promotes an adipocyte-driven phenotype in ovarian cancer cells in a FA uptake
dependent manner [151]. Additionally, inhibition or knockdown of CD36 completely
attenuates this adipocyte dependent malignant phenotype as well as reduces cell
adhesion, invasion, and migration in vitro [151]. Furthermore, human metastatic
ovarian tumors exhibit an upregulation of CD36 expression and inhibition of CD36
via a neutralizing antibody reduced tumor burden in vivo [151].
CD36 is also highly expressed in cervical cancer tissues and data suggests
that CD36 promotes cervical cancer cell proliferation, migration, and invasion both
in vitro and in vivo [220]. Interestingly, TGFβ treatment of cervical cancer cells
increased CD36 expression and downregulated the expression of e-cadherin, a
crucial marker of EMT in several cancers [223]. Additionally, CD36 was also found
to promote breast cancer progression and metastasis and is a poor prognostic
factor for breast cancer patient survival [218, 219]. More specifically, breast cancer
cell proliferation, which is enhanced via exogenous FA treatment, is significantly
reduced in CD36 knockdown breast cancer cell lines [219]. FA treatment of these
CD36 knockdown cell lines did not restore the more proliferative phenotype,
suggesting that CD36 plays a significant role in breast cancer cell proliferation in
a FA uptake dependent manner [219]. Furthermore, CD36 expression is higher in
estrogen receptor rich (ER-rich) cell lines compare to ER-negative cells [218].
Specifically, CD36 promotes the expression of estrogen receptor alpha (ERα),
which can be responsible for increased cell proliferation and apoptosis inhibition,
as well as ERK1/2, which promotes breast cancer cell proliferation and invasion
[224, 225]. Lastly, it was reported that CD36 contributes significantly to metastasis
in oral carcinoma. CD36 high expressing oral carcinoma cells were shown to
promote migration, invasion, and colony formation in vitro [150]. Furthermore,
CD36 high expressing cells were shown to be unique in their ability to initiate
metastasis in orthotopic oral carcinoma xenografts in vivo [150]. Inhibition of CD36
via treatment with a neutralizing antibody completely abolished local invasion and
metastasis of oral carcinoma tumors in vivo [150]. Interestingly, inhibition and
knockdown of CD36 appeared to have no significant effect on primary oral
carcinoma tumor growth, and only attenuated metastatic disease [150].
Together, these data suggest that CD36 plays an important role in the
progression and metastasis of many cancers. However, further investigation is
critical to understand the mechanistic pathways involving CD36’s pro tumorigenic
and metastatic characteristics. Moreover, no previous studies have investigated
the relationship of CD36 driven FA metabolism and that of de novo FA synthesis.
1.12.1 CD36 as a Chemotherapeutic Target
CD36 has been the subject of a few pre-clinical and phase I/II clinical trials
in renal cell carcinoma, non-small cell lung cancer, and soft tissue sarcoma [226].
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Interestingly, each of these clinical trials have targeted CD36 from the perspective
of its binding to TSP-1 [226]. Due to previous data suggesting that binding of TSP1 by CD36 may upregulate anti-angiogenesis, these multiple clinical trials involved
TSP-1 mimetic peptides, which further enhance TSP-1-CD36 downstream
signaling as described previously [208, 209, 226]. These drugs include ABT-510,
ABT526, and ABT-898 as well as CVX-22, and CVX-045 [227, 228]. The ABT
drugs showed promise in pre-clinical in vivo studies but failed in phase II clinical
trials after results showed the drug had no significant effect on tumor progression
and patients displayed severe side effects [228]. Likewise, the CVX drugs showed
significant tumor regression in animal studies, but did not make it past phase I
clinical trials due to adverse side effects and poor response rates [227]. However,
no such clinical trials targeting CD36 in CRC have previously been explored.
Due to the poor efficacy of targeting CD36 via TSP-1 binding, alternate
pathways in which CD36 is involved may be more viable. Since recent studies
have established CD36 as a prominent FA transporter, and since altered FA
metabolism is a hallmark of cancer, targeting the FA transport function of CD36
could be a possible therapeutic strategy [128, 194, 229]. Furthermore, more
investigation into the relationship between CD36 mediated FA uptake and de novo
FA synthesis may yield more potential therapeutic modalities for the treatment of
CRC.
1.13 Hypothesis
The purpose of this project was to understand whether CD36 contributes to
CRC progression and metastasis as well as what relationship CD36 may have with
de novo FA synthesis. The hypothesis is that: (1) Inhibition of FASN via TVB
inhibitors upregulates CD36 and, thus, exogenous FA uptake, (2) CD36
upregulation promotes CRC primary tumor proliferation and survival, and (3) CD36
further enhances CRC invasion and metastasis.
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Table 1.1 CRC survival rates by stage.
Colon Cancer Stage

5-Year Survival Rate

Stage I

92%

Stage IIA

87%

Stage IIB

63%

Stage IIIA

83%

Stage IIIB

64%

Stage IIIC

44%

Stage IV

11%
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Exogenous FA
Uptake

Cellular FA
Pool
FASN
De novo
Lipid synthesis

Figure 1.1 Diagram of cellular FA acquisition. Cell can uptake exogenous FAs
through FA transporters which include the FABPs, FATPs, and CD36 or they can
synthesize them via de novo lipid synthesis which involves the multi-enzyme
FASN.
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Figure 1.2 Structure of CD36. Schematic showing the various post translational
modifications observed with CD36 and highlighting the extracellular FA binding
pocket.
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CHAPTER 2. INHIBITION OF FATTY ACID SYNTHASE UPREGULATES
EXPRESSION OF CD36 TO SUSTAIN PROLIFERATION OF COLORECTAL
CANCER CELLS
2.1 Abstract
Purpose: Altered FA metabolism is a hallmark of cancer and a potential
target for cancer therapy. FA Translocase (CD36) has an important role in FA
metabolism as a FA transporter. FA Synthase (FASN), a key enzyme of de novo
lipogenesis, is associated with poorer prognosis in many cancers including
colorectal cancer (CRC). However, the role of CD36 in CRC as well as its relation
to FA synthesis is not understood. The purpose of our study was to: (i) determine
the functional importance of CD36 in CRC and (ii) investigate the interconnection
between CD36 and FASN expression in CRC cells.
Methods: CD36 and FASN expression was assessed in a CRC tumor
microarray (matched normal colon and primary tumor; 56 cases) as well as
matched normal colon, primary and metastatic tumors by immunohistochemistry.
Cellular proliferation was assessed in control and CD36 shRNA knockdown CRC
cells and in primary CRC cells established from patient-derived xenografts treated
with Sulfo-N-succinimidyl oleate (SSO), a CD36 inhibitor, and TVB-3664, a FASN
inhibitor currently in clinical trial. The effect of CD36 knockdown on tumor growth
was assessed in vitro using a colony formation assay and in vivo using a
subcutaneous xenograft model. Expression of pro-survival and apoptotic markers
was assessed in CD36 knockdown and overexpression CRC cells and in Pt 2402
CD36high and CD36low isogenic cells via western blot. CD36 localization was
assessed via confocal imaging. Effect of FASN knockout on CD36 expression in a
genetically modified mouse model was assessed via qRT-PCR and western blot.
Results: CD36 is overexpressed in CRC primary tumors compared to
normal colon mucosa. Pharmacological inhibition of FASN and shRNA-mediated
knockdown of FASN specifically induces CD36 expression and its translocation to
the plasma membrane in CRC cells and human tissues. Furthermore, deletion of
FASN in APC/Cre mice significantly increases CD36 mRNA and protein
expression. Additionally, knockdown of FASN increase extracellular FA uptake in
a CD36 dependent manner. Cellular proliferation is significantly reduced when
CD36 is inhibited by SSO. Inhibition of CD36 reduces CRC cell proliferation and
colony formation in vitro. Knockdown and chemical inhibition of CD36 decreased
expression of survivin, which has been shown to promote cancer cell survival in
many tumor types. Overexpression of CD36 increased survivin expression in CRC
cells. A higher level of survivin was observed in Pt 2402 CD36high cells as
compared to Pt2402 CD36low cells. Knockdown and pharmacological inhibition of
CD36 significantly reduces the ability of CRC cells to form xenograft tumors in vivo.
Further reduction on CRC cell proliferation in vitro is observed when SSO
treatment is combined with TVB-3664.
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Conclusions: This study for the first time demonstrates that inhibition of
FASN selectively upregulates CD36 in multiple colorectal cancer models including
human tissues, colorectal cancer cells with shRNA mediated knockdown of FA
synthase and genetically modified mouse tissues with heterozygous and
homozygous deletion of FASN. In summary, our study suggests that upregulation
of CD36 expression is a potential compensatory mechanism for FASN inhibition
and that inhibition of CD36 can improve the efficacy of FASN-targeted therapy.
2.2 Introduction
Colorectal cancer (CRC) is the leading cause of non-smoking related
cancer deaths in the world [1]. Altered FA metabolism is a hallmark of cancer and
a potential target for therapeutic intervention [128-130]. FA Synthase (FASN), a
key enzyme of de novo lipogenesis, is significantly upregulated in CRC and
promotes tumor growth and metastasis [153, 230, 231]. Novel FASN inhibitors
developed by Sagimet Biosciences show anti-cancer activity in lung, prostate,
ovarian and colon cancer models in vitro and in vivo [185, 232, 233], and are
currently being tested in phase I/II clinical trials [234-236]. Our studies show antitumor activity of TVB inhibitors in primary CRC cells and CRC patient-derived
xenograft (PDX) models [185, 237].
While most tumors exhibit a shift toward FA synthesis, they can also
scavenge lipids from their environment [130]. FA Translocase (CD36), a
multifunctional glycoprotein, has an important role in FA metabolism as a FA
receptor and transporter [194, 238]. CD36 translocate to the plasma membrane,
where an extracellular domain of the protein binds low density lipoproteins and
transports them across the plasma membrane into the cytosol, thus playing a
critical role in the metabolism of extracellular FAs [194, 238, 239]. CD36 is subject
to various types of post-translational modifications. Glycosylation, ubiquitination
and palmitoylation are involved in regulating CD36 stability and the rate of FA
uptake [240]. Recent studies have shown that CD36 is highly expressed and
enhances the progression of solid malignancies such as breast, ovarian, gastric,
and glioblastoma cancers [149, 151, 241, 242]. Silencing CD36 in human prostate
cancer cells reduces FA uptake and cellular proliferation [243]. Furthermore, the
presence of CD36 positive, metastasis initiating cells correlates with a poorer
prognosis in glioblastoma and oral carcinoma [149, 150]. The contribution of CD36
to CRC progression has not yet been investigated.
Since cancer cells utilize both endogenously-synthesized lipids and
exogeneous FAs [244], and our published data indicate that an enhanced uptake
of dietary FAs may be a potential mechanism of resistance to FASN inhibitors
[185], the goal of this study was to evaluate the interconnection between these two
pathways.
We found that CD36 is significantly overexpressed in CRC and that there is
a correlation between expression of FASN and CD36 in primary human CRC
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specimens. We demonstrate that a decrease in FASN expression is associated
with selective induction of CD36 and that this phenomenon is consistent among
multiple cancer models. Pharmacological and shRNA-mediated inhibition of CD36
decreases proliferation of primary CRC cells in vitro and inhibits tumor growth in
vivo. We also show that CD36 overexpression is associated with upregulation of
survivin, a protein linked to apoptosis resistance, metastasis, bypass of cell cycle
checkpoints, and resistance to therapy [245, 246]. Consistent with our in vitro data,
we show that CD36high-expressing cells, isolated from CRC PDXs, have a
significantly higher level of survivin as compared to CD36low-expressing cells from
the same tumor. Our results also demonstrate that combined inhibition of FASN
and CD36 has a synergetic effect on inhibition of cellular proliferation suggesting
that combination treatment may be a potential therapeutic strategy for CRC.
Together, our findings demonstrate the tightly regulated interconnection
between de novo lipid synthesis and CD36-mediated lipid uptake in CRC
progression during targeted inhibition of FASN, suggesting that inhibition of CD36
may be necessary to improve the efficacy of FASN-targeted therapy.
2.3 Results
2.3.1 CD36 Protein is Overexpressed in CRC
Upregulation of lipid metabolism is a common characteristic of many solid
malignancies, and frequently, enhanced de novo lipogenesis occurs concomitantly
with enhanced import of lipids from the extracellular space [129, 247]. In our
previously published study we showed that FASN is significantly overexpressed in
primary tumor tissues as compared to matched normal colon mucosa using tissue
microarray analysis (TMA) [248]. Using the same TMA, we assessed the
expression of CD36 levels in tumor tissues and found that expression was
significantly higher compared to normal colon mucosa as determined by statistical
evaluation of immunoreactivity scores. We noted that the expression of CD36 is
predominantly cytosolic in primary CRC tumors (Figure 2.1 A-B). Interestingly,
statistical analysis via Spearman Correlation showed a positive correlation
between expression of CD36 and FASN in primary CRC tumor tissues, but it was
not statistically significant (Spearman r =0.21743, n = 56). We have also detected
an increase in expression of CD36 in CRC metastasis to liver and lung (Figure 2.1
C).
Using the Cancer Genome Atlas (TCGA) , we also analyzed FASN and
CD36 mRNA expression. Consistent with protein data, the level of FASN mRNA is
significantly higher in tumor tissues as compared to normal mucosa
(Supplementary Figure S2.1 A). In contrast, we found that the level of CD36
mRNA is significantly lower in cancer tissues as compared to normal tissues
(Supplementary Figure S2.1 B). Interestingly, according to data analysis from the
Human Protein Atlas, the high mRNA expression of CD36 (n = 131) is associated
with poor prognosis in CRC with 5-year survival of 53% patients as compared to
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5-year survival of 64 % patients with low CD36 mRNA expression (n = 466)
(https://www.proteinatlas.org/ENSG00000135218CD36/pathology/colorectal+cancer). Statistical analysis of correlation between
FASN and CD36 revealed a significant negative correlation between FASN and
CD36 mRNA levels in tumor tissues, but not in normal tissues (Figure 2.1 D).
To further delineate association between expression of FASN and CD36,
we analyzed expression of these proteins in fresh human normal colon mucosa,
primary CRC tissues and metastasis (Figure 2.1 E-F). The predicted molecular
mass of CD36 protein is 53kD. However, due to the post-transcriptional
modifications including extensive protein glycosylation, it is widely reported as
approximately 80- 88kD protein [238, 240, 249]. This 80-88kD size will be shown
for all in vitro and in vivo data figures of this manuscript. In the analyzed tissues
sample set, the expression of FASN is higher in primary tumors as compared to
normal mucosa in most cases. Due to FASN being expressed in healthy liver
tissue, it is not surprising to see that its expression is higher in the normal liver as
compared to liver metastasis. CD36 expression seems to be higher or the same in
primary tumors as compared to normal colon mucosa. However, expression of
CD36, particularly its glycosylated form, is much higher in liver metastasis as
compared to normal liver or normal colon mucosa (Figure 2.1 E).
To further analyze CD36 in colorectal cancer we used several PDX models,
which retain the intratumorally clonal heterogeneity and tumor microenvironment
of the parent tumor through passages in mice [185, 250]. We analyzed the
expression of CD36 in nine PDXs established from primary tumors and CRC
metastasis [185], and found that CD36 (88kD) is mostly associated with PDX
established from metastatic tumors with an exception of Pt 2568 which was
established from primary CRC tumor [185] (Supplementary Figure S2.1 C).
Together, these data demonstrate that CD36 is upregulated and exhibit multiple
post-translational modifications in CRC and that there is a significant inverse
correlation between mRNA expression of FASN and CD36 in primary human CRC.
2.3.2 FASN Selectively Regulates Expression of CD36
To test whether alterations in FASN expression affect FA uptake, we
assessed the expression of major FA transporters (FATPs and CD36) in HCT116
NTC and FASN shRNA CRC cells and found that FASN selectively upregulates
mRNA expression of CD36, but not other FAs transporters (Figure 2.2 A). To
confirm that FASN selectively upregulates CD36, we treated fresh CRC human
tissue slices with TVB-3664 and assessed the expression of FA transporters,
including CD36. Consistent with our in vitro data, in all three CRC cases
(Supplementary Table S2.1), we observed that CD36 mRNA expression
increased at least two-fold and as much as four-fold when tissues were treated
with TVB-3664. No changes were observed in expression of the other FA
transporters tested (Figure 2.2 B).
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To further elucidate whether the level of endogenous FA synthesis affects
the expression of CD36, we next treated primary CRC cells from Pt 93 and Pt 130
with TVB-3664 for six days at a concentration of 0.2μM as previously described
[185]. Inhibition of FASN led to an increase in CD36 mRNA and protein expression
in both cell lines (Figure 2.2 C). Consistently, shRNA-mediated knockdown of
FASN in HCT116 and HT29 cell lines led to an increase in CD36 expression in
normal and hypoxic conditions in both cell lines (Figure 2.2 D, Supplementary
Figure S2.2 A). Interestingly, shRNA-mediated knockdown of CD36 does not
affect FASN expression, suggesting a one-dimensional relationship between the
two proteins (Supplementary Figure S2.2 B).
The adenomatous polyposis coli (APC) gene product is mutated in the vast
majority of human CRC and deletion of the APC gene leads to intestinal tumor
formation in mice [251]. In agreement with in vitro data, the analysis of intestinal
tumors from mice with hetero- and homozygous deletions of FASN on C57BL/6Apc/Cre background showed that deletion of FASN significantly upregulates CD36
expression (Figure 2.2 E-F). Collectively, these data suggest that inhibition of
FASN leads to selective upregulation of CD36 expression.
2.3.3 Inhibition of FASN Leads to CD36 Translocation to Plasma Membrane
Confocal imaging of primary Pt 93 CRC cells, control and treated with TVB3664, shows that CD36 protein expression is upregulated and primarily localized
to the plasma membrane when FASN is inhibited by TVB-3664 (Figure 2.2 G). To
confirm these data, primary CRC cells from Pt 93 and Pt 130 were treated with
0.2 μM TVB-3664 for six days in normal or serum-starved conditions and labeled
with CD36-FITC antibody. Flow cytometry analysis was performed; the results
confirmed that inhibition of FASN activity by TVB-3664 led to an increase in
membrane-associated CD36 when compared to control cells in both cell lines in
normal and serum-starved conditions (Figure 2.2 H).
To test whether this upregulation and translocation of CD36 to the plasma
membrane was related to FA metabolism, a FA uptake assay was performed.
HCT116, NTC and FASN shRNA cells were plated and treated with BODIPY FL
and imaged using confocal microscopy. We observed that FASN knockdown
increases FA uptake as indicated by an increase in BODIPY FL staining (Figure
2.2 I). Furthermore, to test that this increase in FAs within the cell was due to CD36
upregulation, we treated NTC and FASN shRNA cells with neutralizing antibody
for CD36. Blocking CD36 has a minimum effect in NTC cells, but significantly
decreases BODIPY FL uptake in FASN shRNA cells, further confirming that
inhibition of FASN increases FA uptake via upregulation of CD36 (Figure 2.2 I).
2.3.4 Inhibition of CD36 reduces CRC Cell Proliferation in vitro
We have previously shown that stable knockdown and pharmacological
inhibition of FASN are associated with a decrease in cellular proliferation and
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tumor growth [153, 185]. However, the observed effects in vivo were not as
prominent as the effects in vitro, suggesting the potential compensatory effects of
diet and exogeneous FA uptake on tumor growth [153, 185]. To test whether
blocking fatty-acid uptake via CD36 has an effect on CRC cell proliferation, primary
CRC cells, Pt 93 and Pt 130, were treated with the chemical CD36 inhibitor
sulfosuccinimidyl oleate (SSO), which binds to CD36 via Lys164 in the
hydrophobic cavity thereby impairing CD36-mediated FA uptake [240, 252], at
100μM in both normal and serum free medium (SFM) conditions. Under both
conditions, primary CRC cells treated with SSO exhibited decreased cellular
proliferation. Interestingly, sensitivity of both cell lines to SSO increased in SFM
(Figure 2.3 A). To evaluate differences in CD36 expression in normal and SFM,
we performed confocal microscopy on Pt 93 cells cultured in normal and SFM
conditions. We found that starvation of CRC cells leads to upregulation of CD36,
which could explain an increase in sensitivity to SSO treatment (Figure 2.3 B).
To assess the effect of CD36 overexpression on apoptotic markers we
performed an Apoptosis Antibody Array. Data showed that overexpression of
CD36 decreased caspase-3 cleavage and increased expression of survivin, a
protein overexpressed in most transformed cell lines and malignancies and
associated with poor clinical outcome (Supplementary Figure S2.3 A) [246, 253].
Consistently, western blot analysis of control and SSO-treated Pt 130 and Pt 93
primary CRC cells showed an increase in cleaved caspase-3 in both cell lines. A
decrease in expression of survivin was observed in Pt 130 cells only
(Supplementary Figure S2.3 B). Consistent with pharmacological inhibition of
CD36, shRNA-mediated knockdown of CD36 lead to a significant decrease in
cellular proliferation and expression of survivin and pAkt in HCT116 cells (Figure
2.3 C-E). Furthermore, shRNA-mediated knockdown of CD36 inhibits colony
formation in the HT29 cell line (Supplementary Figure S2.3 C). Together, these
data demonstrate that CD36 promotes cellular proliferation in CRC.
2.3.5 Inhibition and Knockdown of CD36 Reduces Xenograft Tumor Growth in vivo
To further investigate the role of CD36 in CRC tumor growth, HCT116
subcutaneous xenografts were treated with vehicle or SSO daily for 5 weeks. SSO
treatment lead to significant decreases in tumor volume compared to vehicle
control with no observable SSO toxicity as indicated by unchanged animal weight
(Figure 24 A). Furthermore, consistent with in vitro data, analysis of tumor tissues
treated with SSO show a decrease in survivin mRNA (Figure 2.4 B). FASN mRNA
expression does not change with inhibition of CD36, further supporting the notion
of a one directional relationship between the two proteins. Interestingly, SSO
treatment led to an increase in CD36 mRNA suggesting that the potential
compensation for the lack of functional CD36 was due to antagonistic action of
SSO (Figure 2.4 B).
To further elucidate the role of CD36 in CRC tumor growth, the CRC cell
lines, HCT116, HT29 and HT29 LuM3 (an HT29 cell line that was trained to
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efficiently metastasize to lung via in vivo selection process [254]), were established
as subcutaneous xenografts. Interestingly, in vivo selection led to an increase in
CD36 expression in HT29 LuM3 as compared to parental HT29 cells
(Supplementary Figure S2.4 A). HCT116, HT29 and HT29 LuM3 cells (NTC and
shRNA mediated CD36 knockdown cell lines) were injected subcutaneously into
Nu/Nu mice and tumor growth was measured. Knockdown of CD36 in HCT116
cells markedly attenuated the growth of xenograft tumors compared to NTC
(Figure 2.4 C, Supplementary S2.4 B). In the case of CD36 shRNA #2 and CD36
shRNA #4 cells, we were able to identify microtumors at the site of injections.
Tumor tissues were stained for Ki67, a known marker for tumor cell proliferation
and growth [255]. Ki67 expression was greatly reduced in CD36 knockdown
tumors as compared to control (Figure 2.4 D). In contrast to HCT116 cells, CD36
knockdown in HT29 did not significantly affect tumor growth, suggesting that this
cell line may not be dependent on CD36 due to considerably lower CD36
expression as compared to HCT116 cells (Supplementary Figure S2.4 A, C, D).
However, CD36 knockdown using CD36 shRNA #4 in HT29 LuM3 cells, which
have higher levels of CD36 expression as well as higher metastatic potential [254]
(Supplementary Figure S2.4 A), lead to a more prominent inhibition of tumor
growth and a decrease in tumor weight (Figure 2.4 E). Moreover, consistent with
our in vitro data, qRT-PCR analysis of tumor tissues demonstrates a decrease in
survivin expression when CD36 is knocked down in HT29 LuM3 tumors (Figure
2.4 F). Thus, these data further support the role of CD36 in promoting CRC tumor
growth.
2.3.6 High Expression of CD36 is Associated with an Increase in Survivin in CRC
To further establish that CD36 promotes cellular proliferation via
upregulation of pro-survival pathways, we utilized a PDX tumor model, Pt 2402,
which was established from a CRC metastasis to the lung [185] and is positive for
CD36 expression (see Figure 2.1 E). Tumor tissue from 1st generation Pt 2402
PDX was inoculated into NOD/SCID mice and grown to approximately 1cm3
volume. The tumor was excised, digested as previously described to a single cell
suspension [248], stained with CD36-FITC and sorted via flow cytometry. The top
10% of the brightest green fluorescent protein (GFP) positive cells (117,000 cells),
designated CD36high, and the bottom 10% of GFP negative cells (3,120,000 cells),
designated CD36low, were sorted separately, placed in Matrigel, and sequentially
implanted into NOD/SCID mice and allowed to grow. The tumor established from
CD36high cells grew much larger compared to the CD36low tumor (tumor volume
2419.64mm3 versus 53.57mm3, respectively) (Figure 2.5 A-B). Western blot
analysis of tumor tissues from CD36high and CD36low cells showed an increase in
survivin expression in the CD36high tumors in comparison to the CD36low tumors
(Figure 2.5 C). Interestingly, similar to our data obtained from TMA analysis, we
observed that FASN was higher in CD36high cells as compared to CD36low cells,
further supporting a potential interconnection between these two proteins (Figure
2.5 C). Ki67 staining of Pt 2402 CD36high and CD36low tumors showed a significant
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reduction in Ki67 expression in the CD36low tumors compared to CD36high (Figure
2.5 D).
To confirm that an increase in CD36 expression is associated with an
increase in survivin expression, we overexpressed CD36 in the established
HCT116 CRC cell line. Western blot analysis of HCT116 cells demonstrated CD36
overexpression leads to an increase in expression of survivin and activation of Akt,
an upstream translational regulator of surviving in CRC [256], as well as a
decrease in cleaved-PARP (Figure 2.5 E). Therefore, taken together, our data
suggest that upregulation of pAkt and survivin are potential mechanisms by which
CD36 promotes CRC cell proliferation and tumor growth.
2.3.7 Inhibition of FASN and CD36 in Combination Reduce Primary CRC
Proliferation in vitro
Both de novo synthesized and exogenous FA play important roles in
carcinogenesis [247, 257], To extend our findings that FASN inhibition upregulates
the expression of CD36 and to further test whether inhibition of CD36 can improve
the efficacy of TVB-3664, primary CRC cells from Pt 93 and Pt 130 were treated
with CD36 inhibitor SSO and FASN inhibitor TVB-3664, alone or in combination,
in both normal and serum-starved media. Cellular proliferation was significantly
reduced in both SSO- and TVB-3664-treated cells and was further significantly
reduced in cells that received combination treatment (Figure 2.6 A). Western blot
analysis of CRC cells treated with a combination of TVB-3664 and SSO shows
that combination treatment significantly reduces expression of survivin in PT130
and HCT116 cell lines but not in Pt93 cell line as compared to control or single
agent treatment alone (Figure 2.6 B). Combination treatment was also associated
with reduced expression of cyclin D1 in Pt93 and HCT116 cell lines. Interestingly,
cyclin D1 in Pt130 cells increased expression in combination treatments. This
suggests a different mode of action and sensitivity to SSO and TVB-3664 in Pt130
when compared to other CRC cell lines. Collectively, these data suggest that
inhibition of both FA synthesis and FA uptake may be a potential therapeutic
strategy for CRC. However, further studies are necessary to evaluate the effect of
combinational treatment in vivo.

2.4 Discussion
Our previous studies demonstrate that the effect of FASN inhibition on
cellular proliferation in vitro does not always translate to the same effect on tumor
growth in vivo [153, 185]. Despite a significant decrease in cellular proliferation in
primary CRC cell lines treated with TVB-3664, the efficacy of TVB-3664 in PDX
models was much lower, suggesting a potential compensatory impact of diet on
the effect of FASN inhibitors [185, 237]. Therefore, the goal of this study was to
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delineate the effect of FASN inhibition on exogeneous FA uptake and elucidate the
effect of FA uptake on sustaining cellular proliferation.
Here, for the first time, we report that inhibition of FASN leads to a selective
upregulation of CD36 expression. CD36 enhances FA uptake and FA oxidation
and plays a critical role in cancer cell growth and metastasis [149-151, 258, 259].
Consistent with reports that CD36 is upregulated in breast cancer and glioblastoma
[260], we found that CD36 is highly expressed in CRC as compared to normal
mucosa. Tumor stroma is deficient for CD36 expression [226]. High stromal
content in fresh primary CRC tumors can potentially explain why fresh CRC tissue
analysis shows inconsistent result for CD36 expression in primary CRC as
compared to normal colon. Interestingly, based on tissue analysis, we found that
high expression of CD36 is primarily associated with CRC metastasis suggesting
that metastatic tumors are more dependent on FA uptake as compared to primary
CRC. Our findings are supported by multiple studies showing CD36 involvement
in metastatic disease [150, 261, 262]. Interestingly, even though we have identified
a positive correlation between the protein expression of FASN and CD36 using
TMA analysis, based on TCGA data, there is a significant inverse correlation
between these two proteins at the mRNA levels. Indeed, we found that inhibition
of FASN selectively upregulates CD36 mRNA and protein expression, but not
expression of other FA transporters in multiple models including CRC cells, tumor
xenografts, genetically modified mice and in human tissues. Interestingly, we did
not note any significant changes in FASN expression when the expression of CD36
was altered, suggesting that the level of de novo lipid synthesis is not regulated by
FA uptake via CD36 in our models. Current understanding of the regulation of
CD36 expression is rather limited [263], and how CD36 expression is regulated in
cancer, and in particular in CRC, is not known. Several transcriptional activators
have been implicated in regulation of CD36 expression including peroxisome
proliferator-activated receptors (PPARs), CCAAT/enhancer-binding protein and
HIF-1 [238]. Ongoing studies in our laboratory are investigating CD36 expression
in different cell types in primary and metastatic CRC and potential mechanisms of
CD36 regulation by FASN.
It has been reported that siRNA-mediated inhibition of CD36 decreases
cellular proliferation in MCF-7 breast cancer cells [241]. Additionally, CD36 has
pro-tumorigenic and progression properties in glioblastoma stem cells [149]. In
agreement with these data, our study shows that chemical inhibition and stable
knockdown of CD36 via shRNA in established and primary CRC cells decrease
cellular proliferation. Consistent with data using a specific small molecule CD36
inhibitor, 2-methylthio-1,4-napthoquinone (MTN), in glioblastoma stem cells [149],
inhibition of CD36 with SSO is associated with a decrease in activation of pAkt.
We have also showed that CD36 regulates survivin, a member of the inhibitor of
apoptosis (IAP) family that is highly expressed in most cancer and associated with
a poor prognosis [264]. The pro-survival role of CD36 in CRC is further supported
by data showing that Pt 2402 CD36high cells have a much higher propensity to
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establish xenograft tumors, which grow significantly faster and express higher
levels of survivin, in comparison to CD36low cells.
Interestingly, in a previously published study in oral carcinoma, the effect of
CD36 inhibition was associated with inhibition of metastasis, but not with growth
of primary oral cancers [150]. In contrast to these findings, our study suggests a
critical role of CD36 in CRC proliferation and tumor growth in vivo with both
chemical inhibition via SSO as well as shRNA-mediated knockdown of CD36 in
xenografts using multiple established cell lines.
Novel FASN inhibitors, TVBs, have demonstrated anticancer activity in
multiple preclinical models [129], and TVB-2640 is currently in a number of clinical
trials, including one at the University of Kentucky’s Markey Cancer Center
(https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI2016-01710&r=1). Thus, it is crucial to identify and understand potential resistance
mechanisms to FASN-targeted therapy. The current study demonstrates that
inhibition of FASN leads to upregulation of CD36 expression and its translocation
to the plasma membrane. One of the primary roles of CD36, when located within
the cell membrane, is the transport of FAs [194, 238]. Therefore, this upregulation
of membrane bound CD36 and, consequently, an increase in FA uptake, could be
a potential mechanism of resistance to FASN inhibition. Importantly, our data
demonstrate that the combined inhibition of CD36 and FASN has a synergistic
effect on inhibition of cellular proliferation as well as survivin and cyclin D1, further
suggests that targeting FA uptake may be a potential therapeutic approach to
increase the efficacy of FASN inhibitors.
We have previously reported that the level of FASN expression determines
the sensitivity of tumors to TVB compounds [185]. Consistently throughout this
study, we observed that higher expression of CD36 in HT29 LuM3 cells [254], as
compared to parental HT29 cells, makes these cells more sensitive to CD36
inhibition via CD36 shRNA and increases xenograft tumor growth inhibition
compared to HT29 xenografts. Furthermore, the mutational and metabolic profiles
of tumors determine tumor cell response to multiple therapies including metabolic
inhibitors [265, 266]. Different genetic profiles and metabolic features can explain
the varying levels of response to FASN and CD36 inhibition. Pt 93 and Pt130 cells
have KRAS and V600E BRAF mutations. Pt 130 also carries an FGFR mutation
[185]. The HCT116 cell line is a KRAS mutant, but BRAF wild type, compared to
HT29 which has a V600E BRAF mutation but KRAS wild type [267]. Furthermore,
TVB-3664 seems to have more efficacy in activating PARP cleavage compared to
SSO, suggesting that the inhibition of lipid synthesis leads to activation of
apoptosis through distinct pathways other than those related to the inhibition of
exogenous FA uptake. Our ongoing studies in the laboratory are focused on
identifying the mutational and metabolic features of tumors that would determine
their sensitivity to lipid metabolism targeted therapies.
2.5 Conclusions
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Multiple studies suggest that FA metabolism in adipose tissue is a major
contributor to the etiology of obesity and diabetes [268]. Obesity is associated with
chronic elevation of free FAs (FFA) within the blood serum, which promote insulin
resistance and contribute to the development of systemic hyperglycemia [269].
Interestingly, FASN expression is directly linked to obesity and type 2 diabetes
[270] and CD36 protein expression is upregulated in both obese patients and type
2 diabetics [271]. Therefore, the findings from this study support the idea that
targeting both FASN and CD36 in combination may have therapeutic potential not
only in cancer but also in metabolic disorders such as obesity and diabetes.
This report is the first to describe the functional importance of CD36 and its
indolent role in FA metabolism in the setting of CRC. It is also the first to describe
the interconnection between FASN and CD36 and provides a strong rationale for
further investigation into the interconnection of de novo lipogenesis and FA uptake
that could potentially lead to the development of new therapeutic strategies for
CRC and other solid malignancies as well as, potentially, in some metabolic
disorders.
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Figure 2.1 CD36 is overexpressed in human CRC.
(A-B) Immunoreactivity score of CD36 expression was analyzed in matched
normal colon mucosa and tumor tissues from patients diagnosed with Stage I-IV
CRC (TMA: n=56, *p<0.001 vs. normal tissue). (C) CD36 staining in matched
normal colon mucosa, primary CRC and CRC metastasis to liver and lung
(representative images are shown; liver [n=12] and lung metastasis [n=5]) (D).
Correlations between FASN and CD36 was determined based on RNASeq data
of CRC patient samples (n=22 of normal tissues and n=215 of tumors) from The
Cancer Genome Atlas. (E) Expression of FASN and CD36 in human normal colon
mucosa and tumor tissues. N-normal mucosa, T-primary tumor, L- normal liver
tissue, M-liver metastasis.
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Figure 2.2 Expression of CD36 is selectively regulated by the level of de
novo FA synthesis in CRC.
(A) shRNA-mediated knockdown of FASN leads to upregulation of CD36 mRNA
expression in HCT116 cells. (B) TVB-3664 treatment of CRC tissue slices (18h)
selectively upregulates CD36 mRNA expression. (C) TVB-3664 treatment of Pt 93
and Pt 130 primary CRC cells increases CD36 mRNA and protein expression. (D)
shRNA mediated knockdown of FASN increases CD36 protein expression in
HCT116 and HT29 cells. (E) Relative mRNA expression of FASN and CD36 in
intestinal tumors collected from APC/Cre and FASN+/-/APC/Cre mice. (F) FASN
and CD36 protein expression in intestinal mucosa collected from Apc/Cre and
Apc/Cre mice with hetero- and homozygous deletion of FASN. (G-H) Inhibition of
FASN increases membrane-associated expression of CD36. (G) Confocal images
of FASN and CD36 in control and 0.2μM TVB-3664 treated (6 days) Pt 93 primary
CRC cells. (H) Flow cytometry analysis of Pt 93 and Pt 130 primary CRC cells
treated with 0.2uM TVB-3664 (6 days) in normal and serum free media conditions.
Mean fluorescence for CD36 is shown for representative data from 3 different
experiments (**p<0.01, *p<0.05). (I) FA uptake in HCT116, NTC and FASN
shRNA. Cells wre pre-treated with anti-CD36 antibody or vehicle for 24hrs and
then treated with BODIPY FL for 10 minutes.
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Figure 2.3 Inhibition of CD36 is associated with decreased cellular
proliferation.
(A) Primary Pt 93 and Pt 130 CRC cells treated with 100 μM SSO for 6 days.
Cellular proliferation assays were performed via cell count. Representative data
from 3 experiments is shown (*p<0.05). (B) Confocal images of FASN and CD36
in Pt 93 cells in normal and serum free media (6 days). (C) Expression of proteins
associated with apoptosis and survival in HCT116 transfected with CD36 shRNAs
and analyzed via western blot. D) Cellular proliferation assay with HCT116, NTC
and CD36 shRNA (*p<0.05). (E) qRT-PCR confirmation of CD36 knockdown using
CD36 shRNA #2 (73%) and CD36 shRNA #4 (67%).
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Figure 2.4 SSO treatment and CD36 knockdown inhibit tumor growth in
vivo.
(A) Tumor volume, tumor weight and mouse weight of control and SSO treated
(20mg/kg) mice are shown. SSO was dissolved in 10% PEG and administered in
200 µl dosages via oral gavage daily. 1.0 x 106 cells were injected into NU/NU
mice. Treatment was initiated when tumors reached approximately 100mm3 (day
0). (B) RT-PCR analysis of HCT116 tumors showing the effect of SSO treatment
on CD36, FASN and survivin mRNA expression. (C) Tumor volume of HCT116
NTC and CD36 shRNA #2 and #4 xenografts is shown. 1.0 x 106 cells were
injected into NU/NU mice and tumor growth was measured every 3 days. (D) H&E
and Ki67 staining of HCT116 NTC and CD36 shRNA tumors. (E) Tumor volume
and tumor weight of HT29 LuM3 NTC and CD36 shRNA #4 xenografts are shown.
(F) mRNA expression of survivin in HT29 LuM3 xenografts (analysis of tumors
from 2 mice per group is shown).
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Figure 2.5 High expression of CD36 is associated with an increase in pAkt
and survivin in CRC.
(A) Diagram of Pt 2402 propagation after flow cytometry sorting for CD36high and
CD36low cells. (B) Numbers of CD36high and CD36low Pt 2402 cells for 1st and 2nd
flow cytometry sorts. (C) Protein expression levels of FASN, CD36 and survivin in
CD36high and CD36low Pt 2402 primary cells from 1st flow cytometry sort. (D) IHC
staining for Ki67 in Pt 2402 CD36high and CD36low tumors. (E) Protein expression
levels of FASN, CD36, pAkt, cleaved PARP and survivin in HCT116 CRC cells,
control and CD36 overexpression.
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Figure 2.6 Inhibition of CD36 and FASN have a synergetic effect in reducing
cell proliferation.
(A) Pt 93, Pt 130 and HCT116 cells were treated with SSO and TVB-3664 alone
or in combination for 6 days and cell number was counted. Representative data
from 3 experiments is shown (*p<0.05). (B) Western blot analysis of cells treated
with TVB-3664, SSO or TVB-3664 and SSO in combination.
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Supplementary Figure S2.1
(A) FASN mRNA expression is increased (*p < 0.0001) and (B) CD36 mRNA
expression is decreased (*p < 0.0001) in CRC patient samples in the TCGA
dataset (n=22 of normal tissues and n=215 of tumors). (C) Expression of FASN
and CD36 in PDX tumor tissues.

Supplementary Figure S2.2
Expression of CD36 is regulated by the level of de novo fatty acid synthesis in
CRC. (A) Protein expression of CD36 and FASN in FASN shRNA HCT116 and
HT29 cells in both normal and hypoxic conditions. (B) mRNA expression of CD36
and FASN in HT29LM3 NTC and CD36 shRNA.
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Supplementary Figure S2.3
CD36 upregulates survivin and inhibits apoptotic markers. (A) Effect of CD36
overexpression on apoptotic markers was assessed in HCT116 cells, control and
tdTomato-CD36, using Apoptosis Antibody Array. (B) Primary Pt 130 and Pt 93
CRC cells were treated with 100μM SSO for 5 days in normal medium and
expression of cleaved PARP, cleaved caspase-3, and survivin was analyzed. (C)
3 x 104 HT29, NTC and CD36 shRNA #4, cells were plated in agarose and allowed
to grow for 10 days.

Supplementary Figure S2.4
(A) Expression of CD36 in CRC cell lines. (B) Tumor volume (mm3) of HCT116,
NTC and CD36 shRNA#2 and #4 xenografts shown in Figure 4C. (C) Tumor
growth for HT29 NTC and CD36 shRNA #2 and #4 xenografts. 2.0 x 106 cells were
injected into NU/NU mice and tumor growth was measured every 3 days. (D)
Tumor weight for HT29 NTC and CD36 shRNA #2 and #4 xenografts. (E) mRNA
expression of CD36 and survivin in HT29 xenograft tumors.
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CHAPTER 3. CD36, A FATTY ACID TRANSLOCASE, PROMOTES
METASTASIS VIA UPREGULATION OF MMP28 AND AN INCREASE IN
E-CADHERIN CLEAVAGE IN COLORECTAL CANCER
3.1 Abstract
Purpose: Altered FA metabolism, a hallmark of cancer, continues to be an
attractive target for therapeutic intervention in cancer. Fatty Acid Translocase
(CD36) has an important role in FA metabolism as a FA transporter. We have
previously shown the importance of CD36 in the promotion of colorectal cancer
(CRC) cell proliferation and tumorigenesis as well as its role in the compensation
of de novo FA synthesis inhibition. CD36 has also been shown to play important
roles in migration, invasion and metastasis in gastric, ovarian and oral carcinomas.
Matrix metallopeptidase 28 (MMP28) is a member of the metallopeptidase family
of proteins which is involved in the degradation of the extracellular matrix in various
tissues. MMP28 is relatively novel and poorly investigated in cancer, however it
has been shown to be involved in epithelial to mesenchymal transition (EMT) in
lung and gastric carcinomas. We have previously shown that cell lines with a
higher metastatic potential express higher level of CD36, however, the role of
CD36 in CRC metastasis and its potential regulation of EMT has not been
previously studied. The purpose of our study is (i) to determine the functional effect
of CD36 on CRC metastasis and (ii) to delineate the mechanistic pathways in
which CD36 may regulate CRC metastasis.
METHODS: We utilized HCT116 and HT29 CRC cell lines as well as the
HT29 LuM3-GFP-Luc cell line, which has been established from the HT29 cell line
and has an increased propensity to metastasize to the mouse lung. An increase in
metastatic capacity of HT29 LuM3 is associated with an increase in the expression
of CD36 and MMP28. We utilize parental HT29-GFP-Luc and HT29 LuM3-GFPLuc to overexpress and knockdown CD36, respectively. We also use CD36
neutralizing antibody to block activity of CD36 in HCT116 and HT29 LuM3 cells.
To measure colonization, migration, and invasion we used soft agar colony
formation and trans-well invasion assays. In vivo we utilized the tail-vein injection
model and the orthotopic cecum injection model. We analyzed samples with qRTPCR, western blot, confocal microscopy, and immunohistochemistry.
RESULTS: We found that knockdown of CD36 reduces CRC cell invasion
and colony formation in HCT116 and HT29 LuM3 in vitro. CRC cell invasion and
colony formation were increased with the overexpression of CD36 in HCT116 cells.
Overexpression of CD36 in CRC cell lines increases mRNA and protein expression
of survival and invasion markers including phospho-Akt, as well as MMP28.
Knockdown of CD36 in HT29 LuM3-GFP-Luc cells significantly reduced lung
metastasis in vivo and IHC staining of CD36 knockdown mouse lung tumors show
a decrease in CD36 and MMP28 expression. Additionally, CD36 overexpression
increased tumor growth and metastasis in cecum injected mice. siRNA mediated
knockdown of MMP28 increased e-cadherin expression and decreased the
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products of e-cadherin cleavage CTF1 and 2. shRNA knockdown of CD36
decreases expression of MMP28 and significantly increases expression of ecadherin. Lastly, tissues analyzed from tail-vein injected mice, isogenic PDX
tumors with high expression of CD36, and human CRC primary and liver
metastasis tissues, show that with an increase in CD36 and MMP28 expression,
there is a stark decrease in e-cadherin expression.
CONCLUSION: CRC cells, which have a higher propensity to initiate
metastasis in vivo, express higher levels of CD36 and MMP28. We show that this
upregulation of CD36 and consequently MMP28 represents a unique advantage
for CRC cells to initiate tumor colonies, migrate and invade both in vitro and in vivo.
Furthermore, our study highlights the regulation of e-cadherin via cleavage by
MMP28 in established CRC cell lines, PDXs, and human CRC tissues, suggesting
CD36 via MMP28 may be a desirable therapeutic target for CRC metastasis.
3.2 Introduction
Colorectal cancer (CRC) is the leading cause of non-smoking related
cancer deaths and the second leading cause of all cancer related deaths in both
the United States and the world [1, 2]. Patients diagnosed with late-stage CRC,
Stage III-IV, which exhibit local invasion and distant metastatic disease, have
nearly a 10 fold decrease in 5 year survival rate when compared to earlier stage,
localized disease [18, 19]. Despite advances in the treatment of primary CRC,
there remains a lack of effective therapeutic strategies for late-stage CRC.
Altered FA metabolism is recognized as a hallmark of cancer and multiple studies
suggested targeting this pathway as a potential therapeutic strategy for cancer
including CRC [128-130]. Fatty acid translocase (CD36) plays a significant role in
dietary FA regulation as an exogenous FA transporter [194, 238]. CD36 can be
membrane bound, where it can bind low density lipoproteins and extracellular longchain and ultra-long chain free FAs [194, 272]. CD36 has been implicated in the
promotion of primary tumor proliferation and disease progression in multiple
malignancies including ovarian, glioblastoma, and breast cancers [149, 151, 241,
273]. Recently, our lab has shown the important role CD36 plays in the proliferation
and progression of primary CRC and identified upregulation of CD36 as a potential
mechanism of resistance to FASN-targeted therapy [274].
While compelling evidence exists to support CD36’s role in the promotion
of primary tumor growth and progression in several diseases, there is some
evidence to also suggest that CD36 may play a critical role in cancer metastasis.
CD36 was shown to promote oral carcinoma migration and invasion in vitro and
metastasis in vivo [150]. In fact, an enhanced presence of tumor cells expressing
high levels of CD36 and an increase in metastatic potential is associated with a
poor prognosis and clinical outcome in both glioblastoma and oral carcinoma [149,
150]. Additionally, CD36 enhances in vitro migration and invasion in gastric cancer
cells as well as local invasion and metastasis in vivo in ovarian cancer xenografts
[151, 242, 273]. Furthermore, CD36 has been shown to promote cell growth and
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metastasis as well as epithelial to mesenchymal transition (EMT) in cervical cancer
[275, 276]. However, the potential role of CD36 in CRC metastasis has not been
previously studied.
EMT is the fundamental process to which an epithelial cell acquires a more
mesenchymal phenotype [277, 278]. Aside from the EMT process being utilized
during normal tissue development, wound healing, and tissue repair, EMT has also
been identified as one of the crucial steps involved in cancer metastasis [279-281].
Various molecular pathways and markers are implicated in the regulation of EMT
in CRC, including Snail/Slug, Wnt/B-catenin and particularly the down-regulation
of e-cadherin, a critical component of cell-cell adhesion junctions [282].
Loss of e-cadherin is a key characteristic of EMT initiation in various
cancers including CRC [223, 283]. E-cadherin expression has previously been
shown to be a good prognostic marker for patients with CRC [284]. Furthermore,
loss of e-cadherin increases CRC cell invasion and is correlated with poor survival
rates of CRC patients [285, 286]. Moreover, lower expression of e-cadherin in CRC
patient tumors is associated with tumor differentiation, invasion depth, tumor stage
and lymph node metastasis [287]. Although e-cadherin has several know
transcriptional regulators including both Snail and Slug, it is suggested that ecadherin is strictly regulated post-transcriptionally in CRC, either through
stabilization or cleavage [288, 289]. However, even with multiple studies showing
compelling evidence that lack of e-cadherin expression promotes disease
progression, exact mechanisms of e-cadherin loss in CRC are still poorly
understood.
The matrix metallopeptidase (MMP) family of proteins have been shown to
play an important role in the degradation of several extracellular matrix (ECM)
components [290, 291]. MMP28, one of the newest members of this family of
proteins to be identified, has been shown to be associated with EMT in lung
carcinoma [292]. Furthermore, MMP28 is associated with a poor prognosis and
lower survival rates in gastric cancer and increased expression of MMP28 is
associated with an increase in invasion and colony formation of gastric cancer cells
in vitro and in vivo [293, 294]. Lastly, MMP28 induced EMT in lung carcinoma is
associated with a significant loss of e-cadherin expression [295, 296].
Since previous studies have implicated CD36’s involvement in the
metastatic process and regulation of EMT in multiple cancers, the goal of this study
was to evaluate the contribution of CD36 to CRC metastasis.
We found that CD36 promotes invasion and colony formation of CRC cells
in vitro. We also found that established HT29LuM3 cell line which have a higher
propensity to initiate lung colonies in mice via the tail-vein injection model as
compared to parental HT29 cells, express significantly higher levels of CD36 and
uptake more FFAs in a CD36 dependent manner [254]. Additionally, we also found
that CD36 expression is associated with MMP28 expression in established CRC
45

cell lines and isogenic patient derived xenografts. Our results also show that
knockdown of MMP28 reduces CRC cell invasion in vitro. Furthermore, CD36
knockdown significantly reduces lung colony formation in vivo. Lastly, we found
that CD36 and MMP28 expression are inversely associated with e-cadherin
expression in CRC cells. We show that high level of MMP28 expression is
associated with an increase in the cleavage of e-cadherin and an increase in the
cleavage products of e-cadherin; C-terminus fragment 1 and 2 (CTF1 and CTF2).
CTF1 contains both the transmembrane and cytoplasmic domains of e-cadherin
and is produced after cleavage [297]. CTF1 can then be processed and cleaved
between the cytoplasmic and trans-membrane domains by the Presenilin-1,
resulting in the release of CTF2 [297, 298].
Together these findings implicate that CD36 promotes metastasis via
upregulation of MMP28 and e-cadherin cleavage and, thus, may be a viable
therapeutic target for the treatment of metastatic CRC.
3.3 Results
3.3.1 CD36 Promotes Invasion and Colony Formation in HCT116 Cells
We have previously shown that CD36 promotes CRC proliferation
and survival in in vitro and in vivo [274]. There is also compelling evidence that
CD36 contributes to invasion and migration in various cancers including
glioblastoma, oral carcinoma, gastric, and ovarian cancer [149-151, 241], but
CD36 has not yet been investigated in CRC metastasis. Here, we found that
shRNA-mediated knockdown of CD36 in HCT116 cell line leads to a significant
reduction in invasion as compared to non-targeted control HCT116 cells (Figure
3.1 A, D). Furthermore, when CD36 is overexpressed in HCT116 cells, we
observed a significant increase in cell invasion and colony formation (Figure 3.1
B-D). Together, these data suggest that CD36 is substantially involved in the
invasion and colony formation of established CRC cells.
3.3.2 CD36 Expression is Associated with a More Metastatic Phenotype in
Isogenic CRC Cell Lines
To further investigate any potential role CD36 may play in metastasis
of CRC, we utilized the HT29 LuM3-GFP-Luciferase trained cell line, a cell line
which was serially injected via tail vein in mice and has a significantly higher
propensity to initiate lung colonies than the parental HT29 cell line [254]. We have
previously shown that CD36 is significantly upregulated in the HT29 LuM3 cell line
as compared to parental HT29 [274]. Figures 3.2 A-B demonstrate higher CD36
expression HT29 LuM3 cell line compared to parental HT29 using western blot and
confocal microscopy, respectively. Additionally, confocal microscopy of FA uptake
using BODIPY ™ 558/568 C12 demonstrates that HT29 LuM3 cells uptake more
free FAs than parental HT29 cells in a CD36-dependent manner (Figure 3.2 C).
Furthermore, overexpressing CD36 in the parental HT29 cells significantly
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increases colony formation and colony diameter (Figure 3.2 D). Together these
data suggest that CD36 is upregulated in the HT29 LuM3 cell line and associated
with acquired more invasive and metastatic behavior of this cell line reported
previously [254]. Additionally, the data also suggests that increased expression of
CD36 is also associated with an increase in uptake of extracellular FAs.
3.3.3 CD36 Promotes Lung Colonization and Orthotopic Metastasis in vivo
To more-thoroughly investigate the role CD36 may play in CRC metastasis,
we tested the effect of CD36 on colonization and metastasis in vivo. Utilizing the
HT29 LuM3 model, we established a HT29 LuM3-GFP-Luciferase non-targeted
control (NTC) and CD36 knockdown (shCD36) cell lines and injected these cells
via tail vein into NU/NU (n=5 each) mice and monitored for lung colony formation.
Mice injected with the HT29 LuM3 shCD36 cell line exhibited significantly lower
luciferase reporter bioluminescence signal as compared to mice injected with
HT29 LuM3 NTC cells (Figure 3.3 A). Furthermore, resected lungs from both NTC
and shCD36 injected mice show that mice injected with HT29 shCD36 cells have
substantially lower GFP signal and tumor burden than those injected with HT29
NTC (Figure 3.3 B-C). The levels of CD36 mRNA expression in these cells are
shown in Figure 3.3 D.
To better recapitulate the condition of local invasion and metastasis with
CRC, we also used the orthotopic cecum injection mouse model. The cecum
injection model is well established in vivo model which replicates human disease
with a higher level of accuracy than other ectopic models [299]. To study CD36’s
role in CRC metastasis in a more translational way, we injected 1 x 106 HCT116
p-Lenti-Control or p-Lenti-CD36 overexpressing cells in 50µl of PBS into the cecum
wall of NU/NU (n=5) mice. Our data shows that mice injected with p-Lenti-CD36
overexpressing HCT116 cells exhibited an increase in the number of primary
tumors formed compared to mice injected with p-Lenti-Control cells. More
importantly, we identified GI metastasis in all mice injected with p-Lenti-CD36
overexpressing cells; however, no metastases were found in mice injected with pLenti-Control cells (Figure 3.3 E-G). The level of CD36 overexpression in HCT116
cells is shown in Figure 3.3 H.
Together, the results of animal experiments support our in vitro data and
suggest that CD36 significantly contribute to CRC invasion and metastasis.
3.3.4 CD36 is Associated with MMP28 Expression
Gene enrichment analysis of parental HT29 p-Lenti-Control and p-LentiCD36 overexpression cell lines show an enrichment of pathways involving focal
adhesion, extracellular matrix protein interaction and gap junctions (Figure 3.4 A).
Additionally, RNA-Seq analysis of both cell lines showed that CD36 expression is
associated with matrix metallopeptidase 28 (MMP28) (Figure 3.4 B).
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MMP28 is the newest member matrix metallopeptidase to be identified and
is involved in ECM degradation [292]. MMP28 is associated with metastasis in lung
and gastric cancer [295, 296], but has not yet been studied in CRC. To confirm
RNA-Seq data, we performed qRT-PCR analysis of HT29 LuM0, p-Lenti-Control
and p-Lenti-CD36 overexpression, and HT29 LuM3, NTC and CD36 shRNA, cells.
As shown in Figure 3.4 C, overexpression of CD36 in HT29 cells leads to
significant upregulation of MMP28 mRNA. In contrast, shRNA-mediated
knockdown of CD36 in HT29 LuM3 cells leads to a decrease in MMP28 mRNA
expression. Consistently, HCT116 cells with CD36 overexpression also exhibit
higher levels of MMP28 mRNA expression and inversely, HCT116 CD36 shRNA
cells show a significant decrease in MMP28 mRNA expression (Figure 3.4 D).
Furthermore, HCT116 and HT29 LuM0 cell lines with CD36 overexpression also
display higher protein expression of MMP28, and the pro-survival marker p-Akt
(Figure 3.4 E) [300]. To further support the association between CD36 and
MMP28, we show that HT29 LuM3 cells, which express higher levels of CD36, also
express higher levels of MMP28 protein compared to the parental HT29 LuM0 cell
line as shown by Western blot and confocal microscopy (Figure 3.4 F-G).
Together these data show a strong association of CD36 with MMP28 at
mRNA and protein levels, suggesting that CD36 may indeed regulate the
expression of MMP28.
3.3.5 MMP28 Promotes CRC Cell Invasion and Reduced Expression of ECadherin in vitro
Previously published data suggests that MMP28 plays a critical role in the
regulation of metastasis in lung and gastric cancers. Particularly, MMP28 has been
shown to promote EMT in lung carcinoma and increased of expression of MMP28
is associated with a loss of e-cadherin [295, 296]. Loss of e-cadherin is a wellestablished marker for EMT initiation and poor clinical outcome in various cancers
including CRC [283]. MMP28, however, has not been previously studied and it has
not been mechanistically investigated in relation to e-cadherin in CRC.
To further elucidate the role of MMP28 in CRC metastasis, we established
a transient knockdown of MMP28 in HCT116 cells using MMP28 siRNA. HCT116
siMMP28 cells display a significantly lower ability to invade across a Matrigel
Trans-Well as compared to control cells transfected with scrambled siRNA (Figure
3.5 A). Furthermore, a decrease in MMP28 mRNA expression due to transfection
with MMP28 siRNA leads to a significant increase in mRNA expression of ecadherin when compared to cells transfected with scrambled siRNA control
(Figure 3.5 B). Western blot analysis of the HT29-LuM3-GFP-Luciferase NTC and
CD36 shRNA knockdown cells demonstrates a reduction in MMP28 expression
and an increase in e-cadherin expression further supporting that MMP28 regulates
expression of e-cadherin downstream of CD36 (Figure 3.5 C). The levels of ecadherin expression can be regulated transcriptionally or by e-cadherin cleavage
and shedding [289]. We did not identify any modes of transcriptional regulation of
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e-cadherin, such as through the regulatory proteins Slug or Snail [288, 289], in
response to altered expression of CD36 or MMP28. However, to our surprise,
when we analyzed our HT29-LuM3-GFP-Luciferase NTC and CD36 shRNA
knockdown cells along with control HCT116 cells and cells transfected with
MMP28 siRNA by western blot analysis, we found that MMP28 is not only
associated with a decrease in functional e-cadherin (135 kD), but also associated
with an increase in the cleavage products of e-cadherin, CTF1 and CTF2 (Figure
3.5 C-D). While knockdown of CD36 slightly reduced the levels of CTF1,
knockdown of MMP28 is associated with almost complete abolishment of ecadherin cleavage (Figure 3.5 C-D) suggesting that MMP28 plays a crucial role in
the regulation of e-cadherin, potentially via direct cleavage. These data suggest
that CD36 increases the invasive and metastatic potential of CRC cells by
regulating EMT via the induction of MMP28 and the cleavage of e-cadherin.
3.3.6 Overexpression of CD36 is Associated with an Increase in MMP28
Expression and a Reduction of E-cadherin in vivo and in Human CRC Specimens
To support our data on CD36/MMP28 and e-cadherin axis in CRC
metastasis, we analyzed expression of CD36, MMP28 and e-cadherin in lung
tissues resected from mice injected with HT29 LuM3, NTC and CD36 shRNA, cells
(Figure 3.3 A). IHC analysis demonstrates that reduction of CD36 and MMP28
expression is associated with an increase in e-cadherin expression in tumor
lesions with CD36 knockdown as compared to NTC tumor tissues (Figure 3.6 A).
Our lab has previously shown that isogenic patient derived xenograft (PDX)
tumors, which were established from isolating tumor cells expressing high levels
of CD36 (CD36high), have a higher propensity to grow subcutaneous tumors in vivo
[274]. To further confirm the relationship between CD36, MMP28 and e-cadherin,
we analyzed tissues from Pt2402 CD36high and CD36low PDXs. Western blot
analysis and IHC staining confirms that low expression of CD36 is associated with
low expression of MMP28 and an increase in the level of e-cadherin (Figure 3.6
B-C).
To translate our findings from in vitro and in vivo to human tissues, we
analyzed expression of CD36, MMP28 and e-cadherin in matched normal mucosa,
primary CRC and liver metastasis specimens. Our data shows that as we transition
from normal tissue to primary tumor and then metastasis, we see an increase in
the expression of both CD36 and MMP28 (Figure 3.6 D). Furthermore, we
inversely see a decrease in the expression of e-cadherin as we move from normal
tissues to primary and metastatic tumors (Figure 3.6 D). In agreeance with our in
vitro data, these human tissues also show an increase in the cleavage product of
e-cadherin, CTF2, as disease progresses, suggesting that MMP28, through CD36
regulation, may directly cleave e-cadherin. Furthermore, when analyzing the
expression CD36, MMP28, and e-cadherin in unmatched normal mucosa, primary
and metastatic CRC tissues, we see a pattern of expression which is in agreeance
with our matched tissue data (Figure 3.6 E). Together, this data suggests an
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intriguing relationship between CD36 and MMP28, and that of e-cadherin
cleavage, further supporting our in vitro findings.
3.4 Discussion
Previous investigations from our lab have revealed that CD36 plays an
important role in the survival and proliferation of CRC cells and its specific
upregulation may be a potential compensation mechanism when de novo FA
synthesis is inhibited in CRC [274]. Aside from the pro-survival and tumorigenic
properties of CD36, CD36 has been implied in the promotion of invasion and
metastasis in multiple oncogenic diseases [149-151, 275, 301]. Despite this
knowledge, the role of CD36 in the process of invasion and metastasis of CRC has
not yet been investigated.
In parallel with previous reports that suggest CRC promotes invasion and
metastasis of ovarian and gastric cancer cells in vitro, we found that CD36
promotes colony formation and trans-well invasion of CRC cells in vitro [151, 242].
We also found that CRC cells which exhibit a more metastatic phenotype express
higher levels of CD36 and uptake more exogenous FAs in a CD36-dependent
fashion.
One of the premier studies investigating the role of CD36 in metastasis was
that of Pascual et al. which described the pro-metastatic characteristic of CD36 in
oral carcinoma. It was reported that a subpopulation of oral carcinoma cells which
express high levels of CD36 were unique in their ability to initiate metastasis in
vivo [150]. Additionally, they found that knockdown or inhibition of CD36 did not
affect oral carcinoma primary xenograft tumor growth, but almost completely
abolished local invasion [150]. In contrast to their findings, our previous study
showed that CD36 does play an important role in primary CRC tumor growth, in
particular when endogenously synthesized FAs are limited [274]. However, our
current study is in agreeance with their findings on metastasis, suggesting that
CD36 is also critical for CRC invasion and metastasis. Consequently, our findings
here are also in parallel with several other studies which suggest that CD36
promotes metastasis in vivo [149-151, 242].
It is worth noting that due to CD36’s role in the survival and proliferation of
CRC cells, it is possible that this may also be responsible for the effect of CD36 on
CRC metastasis. Therefore, it is critically important to identify a potential
mechanistic pathway which distinguishes the pro-survival characteristics of CD36
from any pro-metastatic ones. Previously we described that CD36 is associated
with increased levels of the pro-survival marker survivin in primary CRC [274]. We
also showed that an increase in expression of CD36 is associated with an increase
in phosphorylation of Akt [274]. The Akt pathway is implicated in regulation of both
cancer cell survival and metastasis [300]. Previously published study has
implicated that CD36 promotes metastatic disease in gastric cancer via the
AKT/GSK-3beta/beta-catenin pathway [242]. Consistently with this study, we show
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that overexpressing CD36 increases cell invasion and colony formation and is
associated with increased levels of p-Akt in established CRC cell lines. However,
an increase in phosphorylation of Akt alone is not sufficient to describe a metastatic
advantage for CRC.
As previously mentioned, the process of EMT is recognized as one of the
crucial steps involved in cancer metastasis and a hallmark of cancer [229, 280,
302]. The remodeling of the extracellular matrix is critical for cells to escape their
primary environment and enter a system of circulation (lymph or blood) where they
then travel to distant sites and colonize new metastatic tumors [302]. It has been
previously shown that increased FA uptake via CD36 is associated with EMT
progression in hepatocellular carcinoma cells [222]. Furthermore, CD36 has been
shown to promote EMT in cervical cancer through interactions with TGF-beta
pathway [220]. More specifically, treatment of cervical cancer cells with TGF-beta
increased CD36 expression and exhibited a significant loss in the expression of ecadherin [220]. Loss of e-cadherin is critical marker for EMT and a well-established
hallmark of cancer [302]. Interestingly, our studies show that overexpression of
CD36 promotes loss of e-cadherin through a relatively novel member of the MMP
family of proteins, MMP28.
A few members of the MMP family of proteins have been linked to EMT in
multiple diseases [303-305]. Particularly, MMP-3 and 7 have been shown to
promote EMT in breast cancer cells in vitro through direct cleavage of e-cadherin
[303, 305]. In most studies, those tumors expressing higher levels of various MMPs
result in a poor prognosis for patient survival [304]. As previously mentioned,
MMP28 is the newest member of this family of proteins to be identified and is
associated with EMT in lung carcinoma [292]. Additionally, MMP28 is associated
with invasion and colony formation in gastric cancer cells and increased MMP28
expression is a poor prognostic factor for gastric cancer patients [293, 294]. Our
studies show here, for the first time, that CD36 is associated with MMP28
expression in CRC and that MMP28 expression is associated with increased CRC
cell invasion and metastasis. We also show here that MMP28 expression is
associated with a loss of the critical EMT marker e-cadherin. Along with this loss
of e-cadherin, MMP28 expression is associated with increased levels of the
cleaved C-terminal fragments of e-cadherin CTF1 and CTF2 [298]. It is worth
noting that aside from simply being cleavage products of e-cadherin, the CTFs
themselves can act as downstream signaling molecules, such as interacting with
and preventing β-catenin degradation as wells as aiding in the translocation of βcatenin to the nucleus, promoting transcription of various downstream genes [306].
Because of the prominent role that the Wnt/ β-catenin pathway plays in CRC,
further investigation into the MMP28-e-cadherin-CTF association described here
may yield greater information on the mechanisms of CRC progression and
metastasis.
Aside from showing just a direct relationship between MMP28 and ecadherin, we more importantly show that MMP28 downregulation via reduced
51

expression of CD36 significantly upregulates e-cadherin in CRC cell lines, isogenic
PDXs and patient tissues. To our knowledge, this is the first known study to
demonstrate the association of CD36 with MMP28 expression and the loss of ecadherin. Our study is also the first to suggest that MMP28 may be directly involved
in the cleavage of e-cadherin in CRC. Therefore, the data presented here show
that CD36 may play an important role in the regulation of metastasis in CRC
through the upregulation of MMP28 and loss of e-cadherin.
3.5 Conclusions
Late stage CRC, categorized by advanced disease with distant metastasis,
remains one of the deadliest cancers in the United States and the world [1]. New
therapeutic strategies to identify and target tumor cells with higher metastatic
potential is needed to improve the efficacy of treatment and increase overall patient
survival. Together, this study highlights the potential of both CD36 and MMP28 as
therapeutic targets for CRC. Further investigation into the exact mechanistic
regulation of MMP28 by CD36 and MMP28’s interaction with e-cadherin is needed
to potentially develop new more effective treatment strategies for patients with latestage CRC or other solid malignancies.
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Figure 3.1 CD36 promotes invasion and colony formation in CRC cell lines.
(A) Matrigel trans-well invasion assay. Average count of invaded cells/field,
absorbance at 560 nm of de-stained Matrigel trans-well invasion chambers and
raw images of HCT116 NTC and CD36shRNA cell lines are shown. (B) Matrigel
trans-well invasion assay. Average count of invaded cells/field, absorbance at
560 nm of de-stained Matrigel trans-well invasion chambers and raw images of
HCT116 p-Lenti-Control and p-Lenti-CD36 overexpression cell lines are shown.
(C) Quantification and representative images of HCT116 p-Lenti-Control and pLenti-CD36 overexpression soft agar colony formation assays. (D) q-RT-PCR
demonstrating the levels of knockdown and overexpression CD36 in HCT116
NTC/CD36shRNA and HCT116 p-Lenti-Control and p-Lenti-CD36 overexpression
cell lines.
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Figure 3.2 CD36 expression is associated with more metastatic CRC cell
lines.
(A) Western blot analysis of HT29 LuM0 and LuM3 GFP-Luciferase cell lines. (B)
Confocal microscopy images of HT29 LuM0 and LuM3 GFP-Luciferase cells for
CD36 expression (red), nucleus (blue) and actin filaments (purple). (C) FA uptake
assay confocal microscopy images of HT29 LuM0 and LuM3 GFP-Luciferase
control or treated with anti-CD36 neutralizing antibody for 24h (lipid analogue –
red, DAPI – blue). (D) Quantification and representative images of HT29 LuM0 plenti-control and p-lenti-CD36 overexpression soft agar colony formation assays.
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Figure 3.3 CD36 promotes lung colonization and metastasis in vivo.
(A) Representative images and quantification of luciferase assay bioluminescence
imaging in tail-vein injected mice of HT29 LuM3 GFP-Luciferase cells, NTC (n=5)
and CD36shRNA (n=5). (B) GFP imaging and (C) H&E staining of lung tissues of
resected lungs of tail vein injected mice. (D) qRT-PCR quantification of CD36 in
HT29 LuM3 GFP-Luciferase NTC and CD36sh RNA cell lines. (E) Images from
HCT116 control and CD36 overexpression cecum injected mice showing
increased tumor burden and colon metastasis in the CD36 overexpression mice.
(F) H&E staining of the resected primary and metastatic tissues from mice injected
with control and CD36 overexpression HCT116 cells (M–metastasis). (G)
Quantitative analysis of primary cecum tumors and GI metastasis. (H) qRT-PCR
quantification of CD36 in HCT116 p-Lenti-Control and CD36-Overexpression cell
lines. (*p <.05, ** p <.01, ***p <.001)
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Figure 3.4 CD36 regulates expression of MMP28.
(A) Representative gene set enrichment analysis (GSEA) plots generated from
RNA-seq expression data of HT29 p-Lenti Control and HT29 p-Lenti CD36
overexpression cell lines. The top 10 enriched pathway sets are provided
in Supplemental Figure 3.2. Bar codes indicate the location of gene set members
in the ranked list of all genes. ES, enrichment score; NES, normalized enrichment
score; NOM, nominal p-value; FDR, false discovery adjusted p-value. (B) Volcano
plot of HT29 p-Lenti Control and HT29 p-Lenti CD36 overexpression cell lines
showing increased levels of CD36 mRNA associated with an increase in MMP28
mRNA expression. (C) qRT-PCR analysis of CD36 and MMP28 mRNA in HT29, pLenti Control and p-Lenti CD36 overexpression cell lines, and in HT29 LuM3 GFPLuciferase NTC and shCD36 cell lines. (D) qRT-PCR analysis of CD36 and
MMP28 mRNA in HCT116, p-Lenti Control and p-Lenti CD36 overexpression, and
HCT116, NTC and CD36 shRNA cell lines. (E) Western blot analysis of HCT116
and HT29 LuM0 p-Lenti Control and p-Lenti CD36 overexpression cell lines for
CD36, MMP28, p-Akt and total Akt. (F) Western blot of analysis of CD36 and
MMP28 in HT29 LuM0 and HT29 LuM3 GFP-Luciferase cell lines. (G) Confocal
microscopy of HT29 LuM0 and HT29 LuM3 GFP-Luciferase cell lines for actin,
CD36 and MMP28 (*p <.05, ** p <.01, ***p <.001).
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Figure 3.5 MMP28 reduces CRC cell invasion and decreases expression of
functional e-cadherin in vitro.
(A) Normalized average count of invaded cells/field, absorbance at 560 nm of destained Matrigel trans-well invasion chambers and raw images of Matrigel transwell invasion chambers of HCT116, siControl and siMMP28 cell lines. (B) qRTPCR analysis of control and MMP28 siRNA transfected HCT116 cell lines for
MMP28 and e-cadherin. (C) Western blot analysis of HT29 LuM3 NTC and
shCD36 cell lines for CD36, MMP28 and e-cadherin. (D) Western blot for MMP28
and e-cadherin expression. Western blots including e-cadherin cleavage products
CTF1 and CTF2 are shown on separate blots (long and short exposure). (*p <.05,
** p <.01).
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Figure 3.6 Overexpression of CD36 is associated with an increase in
MMP28 expression and reduction in the level of e-cadherin in vivo and
human CRC specimens.
(A) IHC analysis of tissues from tail vein injection of HT29 LuM3 GFP-Luciferase
NTC and shCD36 cell lines shown in Figure 3A. (B) Western blot analysis and (C)
IHC analysis of tissues from Pt2402 PDX, CD36 low and CD36 high, isogenic
tumors for CD36, MM28, and e-cadherin. (D) Western blot analysis of matched
normal (N), primary tumor (PT) and liver metastasis (LM) tissues for CD36,
MMP28, e-cadherin, and CTF2. (E) Western blot analysis of CD36, MMP28, and
e-cadherin in unmatched N, PT, and LM patient tissues.
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CHAPTER 4. FATTY ACID SYNTHASE PROMOTES TUMOR GROWTH VIA
UPREGULATION OF HEXOSAMINE METABOLISM AND O-LINKED
GLYCOSYLATION IN COLORECTAL CANCER
4.1 Abstract
PURPOSE: The Adenomatous polyposis coli (APC) gene is an important
regulatory gene involved in Wnt/β-catenin signaling. Mutations in the APC gene
are associated with CRC tumorigenesis and progression. Animal models have
been developed to study APC-driven tumorigenesis in vivo. Our lab has previously
demonstrated the role of FASN in CRC proliferation and tumorigenesis. However,
FASN has not yet been investigated in regard to APC-driven tumorigenesis.
Therefore, the purpose of this study was to: (i) determine the effect of FASN
deletion on adenoma formation and mice survival in the APC/Villin-Cre mouse
model and (ii) deliniate potential signaling and metabolic pathways effected by
altered FASN expression which may promote tumorigenesis in the APC/Villin-Cre
mouse model.
METHODS: We have developed mouse colonies bred from the APC/VillinCre mouse model in combination with mice containing floxP FASN, resulting in
FASN/Apc/Villin-Cre, FASN+/∆/Apc/Villin-Cre, and FASN∆/∆/Apc/Villin-Cre strains.
Mice from FASN/Apc/Villin-Cre and FASN+/∆/Apc/Villin-Cre strains, both male and
female, were monitored for survival duration. Intestinal tissues from each strain
were also analyzed for FASN expression via IHC and qRT-PCR and adenomas
were counted on the sections of small intestine. RNA transcriptomes from
adenomas collected from all three mouse strains were analyzed via RNA-seq
analysis. Utilizing the list of identified differentially expressed genes (DEGs), the
Gene enrichment analysis was performed. Metabolomic analysis of adenomas
collected
from
FASN/Apc/Villin-Cre,
FASN+/∆/Apc/Villin-Cre,
and
∆/∆
FASN /Apc/Villin-Cre mice was performed using gas chromatography-mass
spectrometry. The protein expression of metabolic enzymes in these mice was
analyzed using the Reverse Phase Protein Array (RPPA). The primary cell lines,
Pt 93 and P t130, were treated with GFPT1 inhibitor azaserine and OGT inhibitor
OSMI1, and cell proliferation and colony formation assays performed. The
established CRC cell line HCT116 was used to knockdown GFPT1 and OGT and
utilized for subcutaneous xenografts in vivo.
RESULTS: The high level of FASN expression is seen intestinal adenomas
developed in Apc/Villin-Cre mice. Heterozygous deletion of FASN leads to a
significant increase in survival of both male and female mice. Consistently,
significantly fewer adenomas formed in Apc/Cre mice with heterozygous deletion
of FASN as compared to APC/Villin-Cre control mice. RNA-seq and gene
enrichment analysis of tissues from FASN/Apc/Villin-Cre, FASN+/∆/Apc/Villin-Cre,
and FASN∆/∆/Apc/Villin-Cre mice show a drastic change in global gene expression
including alterations in pathways involved in cell proliferation, energy metabolism
and CRC initiation and progression. Metabolic analysis of these tissues also
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reveals significant decrease in abundance of multiple metabolites involved in the
TCA cycle, glycolysis, and hexosamine biosynthesis. Importantly, the RPPA data
demonstrate the deletion of FASN in mouse is associated with a significant
decrease in expression of glutamine-fructose-6-phosphate aminotransferase
(GFPT1) and O-Linked N-Acetylglucosamine Transferase (OGT), enzymes within
the hexosamine biosynthesis pathway. More specifically, knockout of FASN
reduces the mRNA and protein expression of both GFPT1 and OGT. Furthermore,
inhibition of GFPT1 and OGT reduces primary CRC cell proliferation and colony
formation in vitro. Lastly, knockdown of GFPT1 and OGT in HCT116 cells reduces
tumor growth in vivo.
CONCLUSIONS: Our data here shows that FASN promotes tumorigenesis
in APC/Cre mouse model. Additionally, FASN also regulates multiple metabolic
processes in these mouse strains, including that of hexosamine biosynthesis.
Furthermore, we found that an increase in GFPT1 and OGT expression promotes
CRC cell proliferation, colony formation and tumor growth. Together, this data
further supports the fact that FASN is a desirable therapeutic target for CRC.
Interestingly, our data here suggests that targeting the regulation of metabolic
processes other than FA metabolism, such as hexosamine biosynthesis, by FASN,
could potentially lead to the development of more efficacious treatment strategies
in CRC. Lastly, our study emphasizes that further investigation into hexosamine
biosynthesis and its regulation is needed to fully delineate the role this pathway
plays in CRC progression.
4.2 Introduction
Colorectal cancer (CRC) is currently the third most diagnosed cancer and
the second most common cause of cancer related deaths in the world [1, 307].
CRC is primarily sporadic, resulting from a variety of environmental factors such
as smoking and obesity, but can also be linked to genetic inheritance [308]. The
Adenomatous polyposis coli (APC) gene is an important regulatory gene which
binds to and sequesters β-catenin in the cytoplasm of the cell, preventing β-catenin
translocation to the nucleus where it would then promote translocation of various
pro-survival and proliferation genes [309]. Mutations in APC have been shown to
be necessary for initiation of familial adenomatous polyposis (FAP) and mutated
APC is suggested in the role of a driver mutation for CRC [309, 310].
Several in vivo models have been developed in an attempt to more
accurately investigate CRC initiation, progression, and metastasis. Some such
models include mutations in and/or alteration in the expression of the APC gene
[310]. A prominent mouse model focusing on APC is the APC multiple intestinal
neoplasia (ApcMin/+) mouse model, in which the APC gene has a truncation
mutation in codon 850. Mice with heterozygous min mutation in APC develop
multiple small intestinal polyps which can progress to adenocarcinoma [311]. This
model is an excellent experimental representation of APC driven FAP and sporadic
colon adenoma development in humans [312].
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Another prominent in vivo model targeting APC is the APC/Villin-Cre mouse
model, in which the APC gene is flanked by loxP sequences and Cre recombinase
is expressed within the crypt epithelial cells of the small and large intestine using
the intestinal specific promoter sequence of Villin [313]. This results in intestinal
specific deletion of APC, which thus leads to a phenotype comparable to that of
the ApcMin mouse model [311, 313]. With this model, it is possible to study APCdriven tumorigenesis in vivo, and potentially identify other pathways which
contribute to this phenomenon.
Altered metabolism is commonly exhibited in CRC and is a hallmark of
cancer and a potential target for therapeutic intervention [128-130, 314, 315]. Fatty
acid synthase (FASN), a critically important enzyme of de novo lipogenesis, has
previously been shown to be upregulated in CRC and involved in tumor
progression and metastasis.[153, 231] Previous studies from our lab show
significant reduction of tumor growth in patient derived xenografts (PDXs) and
primary cell proliferation in vitro when treated with TVB, a novel inhibitor of FASN
developed by Sagimet Biosciences and currently in phase I/II clinical trials [185,
191-193]. However, the role FASN may play in CRC tumor initiation and
development has not yet been studied.
Hexosamine metabolism involves the process known as glycosylation, in
which a glycan is attached to a protein or other functional molecular target and is
an important metabolic pathway involved in the development and regulation of
various tissues and cellular processes [316]. This complex metabolic pathway is a
branch of glycolysis and involves several enzymes. These include the entry and
rate limiting enzyme glutamine-fructose-6-phosphate aminotransferase (GFPT1)
as well as O-Linked N-Acetylglucosamine Transferase (OGT), which attaches the
glycan (β-D-N-acetlyglucosamine (GlcNAc), to a hydroxyl group of serine or
threonine moieties of molecular targets (O-GlcNAc) [316-318]. The resulting
proteins now containing an O-GlcNAc moiety are then used in a variety of cellular
functions including cell signaling and metabolic flux. [317, 319, 320]. Altered levels
of O-GLcNAc have been shown to correlate with cancer progression and altered
glycosylation is also a hallmark of cancer [321, 322]. Furthermore, aberrant protein
glycosylation is a pathological alteration that is frequently associated with onset
and progression of CRC, cancer cells immunogenicity and drug resistance [323325]. It is suggested that O-GlcNAc may be directly modulated by several
processes including FA metabolism [326]. However, any role of de novo lipid
synthesis via FASN in the regulation of cellular glycosylation and their combined
role in CRC has not been previously studied.
We have bred an APC/Villin-CRE mouse along with mice containing a loxPflanked FASN gene expressed with the Villin promoter (FASN/Villin-Cre) resulting
in a colony of mice in which both APC can be genetically deleted along with
heterozygous or homozygous deletion of FASN (FASN+/∆ /Apc/Villin-Cre and
FASN∆ /∆ /Apc/Villin-Cre). We found that mice containing heterozygous deletion of
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FASN in combination with APC deletion live significantly longer than those with
APC deletion alone. Furthermore, we show that both heterozygous and
homozygous deletion of FASN in APC/Villin-Cre mice result in significantly lower
numbers of adenomas in the intestine compared to APC/Cre control. Consistantly,
we demonstrate that deletion of FASN downregulates several pathways including
those involved in cell proliferation, energy metabolism, and CRC initiation and
progression. More specifically, metabolic analysis of mouse tissues with FASN
heterozygous and homozygous deletion reveals a significant alteration of multiple
metabolites involved in glycolysis and the citric acid cycle (TCA). We further show
that FASN regulates important enzymes in hexosamine biosynthesis, specifically
GFPT1 and OGT. Deletion of FASN in mouse tissues significantly downregulates
both OGT and GFPT1 as well as the product of glycosylation, O-GlcNAc. Lastly,
we demonstrate that inhibition of glycosylation through the targeting of OGT and
GFPT1 inhibits CRC cell proliferation, colony formation, and xenograft tumor
growth in vivo.
Together, the data presented here shows that FASN plays a significant role
in the initiation of adenomas in the APC/Villin-Cre mouse model. Additionally,
these results suggest that FASN may regulate hexosamine biosynthesis, which is
an important metabolic pathway in the proliferation and progression of CRC.
These results emphasize the need for further investigation into the mechanistic
regulation of hexosamine biosynthesis by FASN. Furthermore, these results may
provide further insight into the development of new, more-effective therapeutics
against CRC through the targeting of FASN, hexosamine biosynthesis, or both.
4.3 Results
4.3.1 Heterozygous Deletion of FASN Increases Survival and Decreases
Adenoma Burden in vivo
To analyze the potential role of FASN on CRC initiation and adenoma
formation, we utilize the APC/Villin-Cre and FASN/Apc/Villin-Cre mouse models.
IHC analysis of tissues from APC/Villin-Cre mice show that FASN is highly
expressed in tumor tissues (Figure 4.1 A). C57BL/6J mice with LoxP-flanked
FASN alleles were bred with APC/Villin-Cre mice to produce FASN/Villin-Cre,
FASN+/∆ /Apc/Villin-Cre, and FASN∆ /∆ /Apc/Villin-Cre mouse colonies which exhibit
a significant reduction in FASN mRNA expression (Figure 4.1 B). We show that
both male and female mice with heterozygous deletion of FASN live significantly
longer than their APC/Villin-Cre counterparts (Figure 4.1 C). Additionally, FASN+/∆
/Apc/Villin-Cre mice, both males and females, exhibit significant lower adenoma
burden compared to APC/Villin-Cre mice alone (Figure 4.1 D-E).
Together, these data suggest that FASN is an important mediator of tumor
initiation in the APC/Villin-Cre mouse model, implying that CD36 may play an
important role in the initiation of CRC in human patients.
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4.3.2 FASN Deletion Significantly Alters Cellular Gene Expression Profile;
Decreasing Expression of Genes Enriched in Protein Synthesis, Cell Cycle, and
Energy-generating Metabolic Pathways
To delineate the mechanism behind the phenotype observed in the
FASN/Apc/ Villin-Cre mouse model, we performed RNA-seq analysis from tissues
taken from the mouse lines described above. RNA-seq analysis revealed
significant changes in mRNA expression of numerous genes between the
APC/Villin-Cre, FASN+/∆ /Apc/Villin-Cre, and FASN∆/∆ /Apc/Villin-Cre mouse
tissues (Figure 4.2 A-B). Because of this, we also performed gene enrichment
analysis of these mouse tissues which demonstrated significant changes in the
expression of genes involves in cell proliferation, energy metabolism and CRC
initiation and progression (Figure 4.2 C), thus, supporting our data in Figure 4.1.
4.3.3 FASN Knockout Alters Cellular Metabolism
Further analysis of tissues collected from the mouse lines described above
showed several alterations in genes involved in various cellular metabolic
processes. Reverse phase protein array (RPPA) analysis revealed significant
changes in genes involved in the TCA cycle, glycolysis, and hexosamine
biosynthesis (Figure 4.3 A-B). Analysis of cellular metabolites was performed
using gas chromatography-mass spectrometry (GCMS). (Figure 4.3 C). We are
currently analyzing this data and have already identified significant changes in
metabolites within glycolysis and its branching pathways and TCA cycle.
Together, these data suggest that FASN is an important regulator of not
only FA metabolism directly, but also various other metabolic processes in CRC,
which could have significant impact on CRC cell growth.
4.3.4 Overexpression of FASN Increases Expression of GFPT1 and OGT in vivo
Altered glycosylation is frequently associated with the onset and
progression of CRC [323-325]. Interestingly, RPPA analysis showed that
hexosamine biosynthesis was altered in FASN knockout mouse tissues,
specifically two critical genes necessary for hexosamine biosynthesis, GFPT1 and
OGT (Figure 4.4 A). To further elaborate on this, we analyzed protein expression
of genes related to hexosamine biosynthesis as well as the product of this
pathway, O-GlcNAc, and found that several genes and O-GlcNAc were
downregulated in FASN knockout mouse tissues (Figure 4.4 B-C).
Our lab has also established an inducible CRE mouse model, where the
Cre recombinase enzyme is expressed with an ERT2 promoter, allowing for
expression of Cre only in the presence of tamoxifen. When bred with our FASN
mouse strains, the results are the, FASN+/∆ /Apc/Villin-Cre -ERT2 and FASN∆ /∆
/Apc/Villin-Cre-ERT2 strains, which upon administration of tamoxifen, both FASN
and APC are deleted from the genome. Utilizing this model, we analyzed the
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mRNA and protein expression levels of GFPT1 and OGT and found that when
FASN is knocked out via tamoxifen, both GFPT1 and OGT expression is
significantly reduced and comparable to that of the FASN+/∆ /Apc/Villin-Cre and
FASN∆ /∆ /Apc/Villin-Cre strains (Figure 4.4 D-E).
These data suggest that FASN significantly regulates hexosamine
biosynthesis via the regulation of GFPT1 and OGT gene expression, implying that
FASN may regulate CRC initiation and progression not only through direct FA
metabolism, but also through glycolysis.
4.3.5 High Expression of GFPT1 and OGT is associated with an increase in CRC
Proliferation and Tumorigenesis
To delineate the effect of hexosamine biosynthesis in CRC, we utilized the
primary CRC cell line Pt93 established in our lab. The drug Azaserine is a chemical
inhibitor of GFPT1 [327]. Treatment of Pt93 with varying concentrations of
Azaserine results in a significant reduction in cell proliferation (Figure 4.5 A).
Additionally, treatment of Pt93 cells with OSMI-1, a chemical inhibitor of OGT, also
significantly reduced proliferation (Figure 4.5 A). Furthermore, treatment of both
drugs on Pt93 also greatly reduced soft agar colony formation (Figure 4.5 B).
Moreover, knockdown of GFPT1 and OGT in the established CRC cell line
HCT116 reduced subcutaneous xenograft tumor volume and tumor weight in vivo
(Figure 4.5 C-D).
Cumulatively, this data suggests that hexosamine biosynthesis is a critical
component to CRC proliferation and progression and that the enzymes GFPT1
and OGT play a crucial role in this process.
4.4 Discussion
The APC/Villin-Cre mouse model allows investigators to study APC driven
adenoma formation in vivo [312]. Previous studies from our lab have demonstrated
the role of FASN in CRC cell proliferation and tumor growth. [153, 185]. However,
FASN has never been investigated regarding APC driven adenoma formation in
animal models. Here for the first time, we demonstrate that FASN is significantly
upregulated in APC/Villin-CRE mice. Additionally, we established FASN+/∆
/Apc/Villin-Cre and FASN∆/∆ /Apc/Villin-Cre mouse strains and found that when
FASN expression is reduced, these mice exhibit significantly reduced tumor
burden and survive longer than their APC/Villin-CRE counterparts. Additionally,
through RNA-seq, gene enrichment, and RPPA analysis, we show that FASN
knockout reduces the expression of several metabolic genes involved in the TCA
cycle, glycolysis, and hexosamine biosynthesis.
Dysregulation of hexosamine biosynthesis, otherwise known as
glycosylation, is frequently associated with the onset and progression of CRC [323325]. Two prominent enzymes involved in glycosylation are GFPT1, the rate
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limiting enzyme, and OGT, the enzyme responsible for the final step of
glycosylation, producing O-GlcNAc [316-318]. It is suggested that levels of cellular
O-GlcNAc may be directly regulated by FA metabolism. However, the role of
GFPT1 and OGT in disease progression as well as any potential regulation of
glycosylation by FASN has not yet been investigated in CRC. Our data here shows
that when FASN expression is reduced is mouse tissues, both GFPT1 and OGT
mRNA and protein expression is reduced. Furthermore, in the same tissues we
also demonstrate that with a reduction in both GFPT1 and OGT, we see a
reduction in the number of glycosylated proteins. This data suggests that FASN
may not only regulate FA metabolism but also hexamine biosynthesis in
APC/Villin-CRE mice.
To further elaborate on the role of GFPT1 and OGT in CRC tumorigenesis,
we demonstrate here for the first time that inhibition of GFPT1 and OGT reduce
cell proliferation and colony formation in vitro. Additionally, we show that
knockdown of both GFPT1 and OGT reduced tumor volume and tumor weight in
subcutaneous xenografts. These data further support the hypothesis that
hexamine biosynthesis is an important metabolic pathway in the development and
progression of CRC.
4.5 Conclusions
In summary, the APC/Villin-CRE mouse model in an excellent tool for the
investigation of APC driven tumorigenesis [312]. Further investigation into the
mechanistic drivers of this phenomenon could potentially provide new therapeutic
avenues for the treatment of CRC. Our data here emphasizes the important role
FASN plays in this process through the regulation of hexosamine biosynthesis.
Furthermore, hexosamine biosynthesis itself appears to be a significant contributor
to CRC progression and further understanding of this pathway is necessary for
more efficacious treatment of CRC. Lastly, our data suggests that further
understanding of the role FASN plays in APC driven tumorigenesis and targeting
this association could lead to improved survival rates for patients with CRC.
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Figure 4.1 Heterozygous Deletion of FASN Increases Survival and
Decreases Adenoma Burden in vivo.
(A) FASN expression in Apc/Cre mice. (B) Cre-mediated knockout of FASN in
mouse intestinal tumors. (C) The effect of Villin-Cre-mediated heterozygous
deletion of FASN in mouse intestinal and colon tissues on mice survival. (D) The
effect of Villin-Cre-mediated heterozygous deletion of FASN in mouse intestinal
and colon tissues on formation of mouse adenomas. Analysis10 cm sections of
distal intestine from Apc/Cre mice and mice with heterozygous deletion of FASN.
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Figure 4.2 FASN Deletion Significantly Changes Cellular Gene Expression.
(A) Venn diagram displaying the overlapping genes identified in tumors from
Apc/Villin-Cre mice and Apc/Villin-Cre mice with heterozygous and homozygous
deletion of FASN. (B) Scatter plots showing several DEGs in Apc/Villin-Cre mice
and Apc/Villin-Cre mice with heterozygous and homozygous deletion of FASN.
Significantly DEGs are indicated in colors. Red and blue dots are up- and
downregulated genes, respectively. (C) Representative gene set enrichment
analysis (GSEA) plots generated from RNA-seq expression data of Apc/Cre and
FASN knockout mice. The bar codes indicate the location of the members of the
gene set in the ranked list of all genes. ES, enrichment Score; NES, normalized
enrichment score; NOM, nominal p-value; FDR, false discovery adjusted p-value.
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Figure 4.3 FASN Knockout Alters Cellular Metabolism.
(A) Heat map demonstrating expression of metabolic enzyme as determined by
the Reverse Phase Protein Array (RPPA) analysis (performed by Redox
Metabolism Shared Resource Facility and analyzed by Biostatistics &
Bioinformatics Shared Resource Facility). (B) The level of FASN expression by
Western Blot of mouse tumors used for the RPPA analysis. (C) Heat map of
metabolites determined by Gas Chromatography-Mass Spectrometry (GCMS) in
mouse adenomas (performed in collaboration with Dr. Ramon Sun laboratory).

68

Figure 4.4 FASN Regulates the Expression of GFPT1 and OGT in vivo.
(A) RNA-seq analysis volcano plots showing significant differences in the mRNA
expression of GFPT1 and OGT in FASN knockout mouse tissues. (B) Western blot
analysis of various enzymes involved in hexosamine biosynthesis from Apc/VillinCre, FASN+/∆ /Apc/Villin-Cre, and FASN∆/∆/Apc/Villin-Cre tissues of mice. (C)
Western blot analysis of O-GlcNAc in mouse tissues described above. (D) mRNA
and (E) protein expression of FASN, GFPT1, and OGT in the inducible Apc/ VillinCre-ERT2, FASN+/∆/Apc/ Villin-Cre-ERT2, FASN∆/∆/Apc/ Villin-Cre-ERT2 mouse
models.
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Figure 4.5 GFPT1 and OGT Regulate CRC Proliferation and Tumorigenesis
(A) Cell proliferation assays of Pt93 cell treated with azaserine, and OSMI. (B)
Colony formation assays of Pt93 cells treated with azaserine and OSMI-1. (C)
HCT116 NTC, shGFPT1, and shOGT xenograft tumor volumes and (D) tumor
weights.
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CHAPTER 5. CONCLUSIONS
Altered fatty-acid metabolism is a hallmark of cancer and has been
implicated in CRC progression and metastasis [128-130]. Inhibition of de novo FA
synthesis through targeting FASN via TVB has shown some promise in pre-clinical
studies [191-193]. However, despite of presence of high FASN expression in
tumors, only 30% of PDXs show a positive response to TVB treatment [185]. Thus,
there may be alternative compensatory pathways that contributes to TVB
resistance. Such pathways may include the uptake of exogenous FAs via FA
transporters. CD36 is a prominent exogenous FA transporter and has been shown
to promote tumor progression in multiple diseases [149-152, 217-221]. Therefore,
the purpose of my studies was to investigate any potential role of CD36 in CRC
primary tumor progression and metastasis as well as any role CD36 may have in
the resistance of FASN inhibition to possibly define new therapeutic targets for
CRC treatment.
5.1 CD36 in Primary CRC
CD36 is upregulated in primary CRC cells, patient tissues, and patient
derived xenografts. CD36 is associated with an increase in the proliferation of
established and primary CRC cell lines. High expression of CD36 also promotes
tumor growth in vivo in an isogenic patient derived xenograft model. Consistently,
pharmacological inhibition of CD36 with SSO decreases cell proliferation in vitro
and tumor progression in vivo. This data is in parallel with most of the current
literature, which is suggestive that CD36 plays an important role in primary tumor
survival and disease progression in multiple cancers [149-152, 217-221].
Furthermore, increased expression of CD36 was associated with increases
in the pro-survival markers survivin and p-Akt. Survivin, a member of the inhibitor
of apoptosis (IAP) family of proteins, is involved in the inhibition of various
caspases including caspace-3 and 7, and thus inhibiting programmed cell death
[328]. Akt is a crucial component of the PI3K/Akt/mTOR pathway, which is an
important regulatory pathway for cell proliferation and survival [329]. This data is
in agreement with previously published literature, which implicated CD36 in the
regulation of the Src/PI3K/AKT/mTOR signaling pathway in HCC [221]. The data
from this first study suggest that CD36 plays a role in proliferation and
tumorigenesis in primary CRC.
During the investigative process of these findings, another manuscript
studying the potential role of CD36 in CRC was published [330]. Interestingly, Y.
Fang et.al. found that CD36 expression inversely correlates with CRC progression
and they demonstrated that CD36 overexpression decreases CRC cell viability and
colony formation [330]. Their data also suggest that CD36 knockdown increases
cell viability and colony formation. Furthermore, they state that CD36 reduces
glycolysis through inhibition of β-catenin/c-myc signaling [330]. This data is in
contrast with previous literature in other diseases, which imply CD36 contributes
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to increased glycolysis in HCC, and is in direct contrast with our findings here. One
potential explanation to these varying results in CRC could be that between the
two studies, a variety of CRC cell lines were used, none of which were used in
both investigations. Our studies utilize HCT116, HT29 and isogenic HT29 cell lines
LuM0 and LuM3, as well as primary cell lines established from PDX tumors in our
laboratory. We also utilized a variety of patient tissues and other PDX models
[274]. In contrast, Y. Fang et al. used 4 established CRC cell lines: SW480, LoVo,
RKO, and CACO2 [330] and did not utilize HCT116 and HT29 cells which are most
frequently used in publications for CRC. Even among the few CRC cell lines used
within our investigation, we noted differences in the expression of CD36. Variances
in the mutational profiles, metabolic reprogramming, and gene expression of these
cell lines may account for the conflicting results observed between the two
manuscripts.
5.2 CD36 Compensates for FASN Inhibition
Previous studies from our lab have shown that inhibition of FASN via TVB3664 reduces cell proliferation in vitro [153, 185]. However, when analyzing the
efficacy of TVB in pre-clinical in vivo studies using PDX models, we noted that only
30% of PDX tumors responded positively to TVB-3664 [153, 185]. Since mice
consume a dietary FAs present in their normal chow, we hypothesized that
pathways involved in the uptake of exogenous FAs are of particular interest to
investigate the mechanisms of resistance to FASN-targeted therapy.
CD36 is a well-defined FA transporter expressed in various tissues [120].
Analysis of the TCGA data base reveals that on the mRNA level, CD36 and FASN
share an inverse relationship in CRC [274]. In the presence of FASN inhibition or
knockdown, we show that CD36 is significantly upregulated in established and
primary cell lines, tumor xenografts, genetically modified mouse models with
knockout of FASN, and human tissues [274]. Furthermore, this upregulation of
CD36 is extremely specific, with no significant change in the expression of other
prominent FA transporters when FASN function is reduced in all models described
above [274]. Additionally, knockdown of FASN upregulates the uptake of
exogenous fluorescent FA analogues, and this increase in FA uptake is directly
dependent on CD36 as demonstrated using a CD36 neutralizing antibody [274].
Together, the data presented here provides compelling evidence that inhibition of
FASN directly upregulates CD36 to increase exogenous FA uptake and
compensate for the lack of de novo FA synthesis. This relationship between FASN
and CD36 had not yet been investigated in CRC.
Interestingly, our data here is further supported by one other study. It was
shown that breast cancer cell lines which are resistant to lapatinib, a targeted
therapeutic for HER2 positive breast cancer cells, markedly develop resistance to
FASN inhibition [331, 332]. To note, it has been shown that FASN can be regulated
by HER2 via phosphorylation in HER2 positive breast cancer [333]. It was
suggested that metabolic reprogramming of these cells contributes to their
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resistance to both lapatinib and FASN inhibition. Indeed, it was shown through
microarray analysis that CD36 is significantly upregulated in lapatinib resistant
breast cancer cell lines and that inhibition of CD36 significantly reduces cell
viability and proliferation [331]. Furthermore, inhibition of CD36 via a neutralizing
antibody in mouse xenograft models sensitizes breast cancer tumors to lapatinib
[332]. Lastly, it was also demonstrated that patients treated with anti-HER2 therapy
display a significant upregulation in CD36 expression [332]. Together, these data
support our findings in that, with the targeting of HER2 and thus FASN, breast
cancer cells reprogram their metabolism to become more reliant on the uptake of
exogenous FAs through CD36.
Due to the increasing interest in targeting FA metabolism in the treatment
of cancer, understanding the relationships between exogenous FA uptake and de
novo FA synthesis is critical. From the data presented here, we suggest that further
understanding of the relationship between FASN and CD36 is necessary to
increase the efficacy of FASN-targeted therapies as well as those drugs already
approved for the treatment of other cancers, such as lapatinib. Furthermore,
delineating the mechanisms behind this relationship may help to develop entirely
new therapeutic approaches for the treatment of CRC, other cancers, or other
metabolism dysregulated diseases.
5.3 CD36 and CRC Metastasis
TMA analysis of normal colon as well as primary and metastatic CRC
tissues showed an increase in CD36 expression in primary CRC and further
upregulation in metastasis [274]. Furthermore, CD36 expression in metastatic
tissues could be characterized with a stark increase in membrane associated
CD36 [274]. Because of this association of CD36 expression with metastatic
tissues, we developed a hypothesis that CD36 expression contributed to CRC
progression and metastasis.
Indeed, CD36 overexpression in CRC cell lines increased cell invasion and
colony formation in vitro and CD36 expression was associated with cells that
exhibit a higher metastatic potential [274]. Furthermore, CD36 knockdown reduced
lung colony formation and CD36 overexpression increased local CRC cell invasion
and metastasis in cecum injected mice [274]. It is logical to think that increased
CD36 expression in CRC confers metastatic potential through increased FA
uptake and, thus, more energy resources and building blocks for cell membranes
in these more metabolically demanding and highly proliferative cells. However, it
is possible that CD36 may also regulate other processes involved in metastasis,
such as EMT.
We found that CD36 expression is associated with the newest member of
the matrix metallopeptidase family of proteins, MMP28 [290, 292]. We also show
that knockdown of MMP28 reduces CRC cell invasion comparable to that of CD36
knockdown. Current literature on the details of MMP28 function are limited due to
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its novelty; however, like other MMPs, it is implicated in the regulation of various
extracellular matrix components [290]. Most interestingly, we found that MMP28
expression is inversely associated with e-cadherin expression, an important
marker for EMT in CRC [284]. As previously mentioned, e-cadherin loss is a poor
prognostic factor for CRC patients, and it is associated with tumor invasion and
lymph node metastasis [287]. It was previously shown that MMP28 is associated
with EMT and e-cadherin loss in lung carcinoma [295, 296]. However, any potential
association of MMP28 with e-cadherin has not yet been investigated. Moreover,
the exact mechanism by which MMP28 may regulate the expression of e-cadherin
has not yet been fully elucidated. We demonstrate here, for the first time, that
MMP28 expression is not only associated with loss of functional e-cadherin, but
that it is also associated with an increase in the products of e-cadherin cleavage,
CFT1 and CFT2 [297]. This striking insight suggests that MMP28 may very well
directly cleave functional e-cadherin. The implications of these findings are
significant, as the CD36-MMP28-e-cadherin association may be a novel
mechanistic pathway of EMT regulation in CRC.
With metastatic CRC survival rates remaining at terribly low levels, insight
into mechanisms by which CRC tumors initiate metastasis are crucial for future
treatment of CRC patients. Further investigation into the regulation of MMP28 by
CD36 may provide the necessary information to successfully develop therapeutics
against this phenomenon.
5.4 CD36 Functions as a FA Transporter in Cancer
Mechanistically, we show an increase in exogenous FA uptake as well as
increases in both survivin and p-Akt and as described above, which mostly agrees
with previous literature with some slight controversy [330]. The results here lead
to the development of the hypothesis that CD36 enhances primary CRC
proliferation and survival directly through the uptake of exogenous FAs, and thus
increased FA metabolism. However, further investigation into exact metabolic
pathways which are utilized in cells and tumors with high expression of CD36 is
needed to definitively test this hypothesis.
Compelling evidence exists from multiple previous publications that CD36
plays an important role in tumorigenesis and cancer progression via FA transport
[219, 220, 276]. As previously mentioned, it was shown that FA treatment of breast
cancer cell lines enhances cell proliferation. Furthermore, knockdown of CD36
abolishes cell proliferation after FA treatment, suggesting that the more
proliferative phenotype observed with FA treatment is CD36 dependent. [219]. In
addition to breast cancer, CD36 was shown to contribute to cervical cancer tumor
growth and progression in a FA dependent manner. More specifically, cervical
cancer xenograft mice fed a diet high in oleic acid exhibit increased tumor volume
and weight [276]. However, when CD36 is inhibited, the tumorigenic phenotype
observed in oleic acid fed mice is prevented. Furthermore, overexpression of CD36
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in cervical cancer xenograft mice, which were fed normal diet, results in similar
tumor growth as just high oleic acid diet alone [276].
Interestingly, the pro-tumorigenic effect of CD36 as a FA transporter are not
strictly due to just the transport of various FAs. In fact, it was shown that the binding
and transport of FAs by CD36 also induces several downstream signaling
cascades which also contribute to disease progression [210, 221, 276]. For
instance, in cervical cancer cells, CD36 FA transport activates ERK 1/2 signaling
through activating Src-kinase, as described previously [210, 276]. Furthermore,
CD36 was found to enhance glycolysis in HCC through downstream activation of
the Src/PI3K/AKT/mTOR signaling pathway [221]. Our data suggest that a similar
signaling function is also present in CRC, as we show an increase in both survivin
and p-Akt when CD36 is overexpressed in CRC cells.
Our results support the literature in that CD36 promotes CRC through the
uptake of exogenous FAs and the upregulation of multiple pro-survival pathways.
Further investigation into the exact metabolic rewiring that occurs due to CD36mediated FA uptake is needed and would likely shed new light on FA metabolism
as a therapeutic target in CRC. Together, our data and the literature suggest that
targeting CD36 from the perspective of a FA transporter may yield significant
insight into this phenomenon and possibly provide new therapeutic strategies for
CRC and other oncogenic diseases.
5.5 Potentiality of CD36 Targeted Therapies
As mentioned previously, there were multiple clinical trials which had
targeted CD36 in relation to its role in binding TSP1 and its role in angiogenesis
[226]. More specifically, these therapeutics were designed as TSP1 mimetics,
mimicking the structure of TSP1 to further increase TSP1-CD36 mediated
signaling and, thus, inhibiting angiogenesis [208, 209, 226]. Although each drug
had shown promise in pre-clinical studies, unfortunately, each of those previous
clinical trials resulted in early termination due to adverse side effects, as well as
little to no efficacy [227]. To date, there have been no pre-clinical or clinical trials
developed aimed at targeting CD36 in cancer from the perspective of FA transport.
As the studies presented here suggest, targeting CD36 can both reduce
CRC cell proliferation and inhibit xenograft tumor growth in vivo. Additionally, CD36
contributes significantly to invasion and colony formation in vitro, and lung colony
formation and orthotopic xenograft metastasis in vivo, suggesting that it is a
potential target for metastasis. Furthermore, we show that inhibiting CD36 function
directly decreases exogenous FA uptake, supporting the hypothesis that CD36
promotes primary and metastatic CRC through the advantageous uptake of
exogenous FAs which can then be used as a source of energy as well as building
blocks for cell membranes [274]. These attributes strongly support the idea of
developing and further investigating the effectiveness of chemotherapeutic targets
against CD36, particularly in its role as a FA transporter.
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Previous investigations into the role of CD36 in oral carcinoma revealed that
CD36 is a major contributor to oral carcinoma metastasis [150]. Interestingly, in
contrast to our findings in CRC, this study shows little to no effect on primary oral
carcinoma tumor growth when CD36 was inhibited or knocked down [150].
Because of these earlier findings, members from this lab have since founded a
company, Ona Therapeutics, which is focused on the investigation of metastasis
in numerous oncogenic diseases with the primary aim of developing
chemotherapeutics against dysregulated lipid metabolism (Figure 5.1) [334]. As
their flagship project, CD36 is currently their primary focus with the hopes of
developing agents to inhibit metastasis initiation in various cancers. Our work
presented here shows substantial evidence supporting their current work and
suggests that CD36 is a potential therapeutic target in CRC, not only for metastasis
but also for primary CRC development and progression.
To reiterate the potential significance of CD36 as a therapeutic target, I will
stress again the important role CD36 plays in the compensation of de novo FA
synthesis inhibition. Currently, the results described here regarding this
relationship could potentially have significant clinical impact. The FASN inhibitor
TVB and its various analogues are being tested in several pre-clinical and clinical
trials [191-193]. Current data not only suggests that not all patients will respond
well to FASN-targeted therapy, but also that high expression of FASN alone is not
enough to determine whether a patient will respond positively to TVB. Identifying
CD36 as a potential compensatory mechanism to FASN inhibition may allow for
more efficacious treatment in combination with TVB.
Chemotherapeutic targets against CD36 should be developed based on our
results and the overwhelming evidence of CD36 as pro-tumorigenic in the
literature. Together, the results shown here support the need for further
investigation of CD36 to treat CRC more effectively. This further understanding will
allow investigators, such as those working at Ona Therapeutics, to better develop
potential drugs to target CD36.
5.6 FASN Promotes APC-Driven Tumorigenesis
FASN expression is upregulated in animal tissues with Cre-mediated
deletion of the APC gene. Heterozygous deletion of FASN in Apc/Villin-Cre mice
leads to a significant increase in animal survival and a decrease in intestinal tumor
burden. This data suggests that FASN may play an important role in tumor initiation
in APC-driven tumorigenesis.
Investigations in the molecular drivers for both familial and sporadic CRC
have resulted in several suspect genes. One such is APC, and mutations in APC
and its role in regulating Wnt/β-catenin signaling, have been shown to be
necessary for the initiation of FAP, and aberrant Wnt/β-catenin signaling is present
in nearly 90% of human CRC [309, 310, 335]. The in vivo APC/Villin-Cre mouse
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model is an excellent tool for investigating this phenomenon [312]. Our data here
suggests that not only is APC driving tumorigenesis through increased Wnt/βcatenin signaling, but lack of wild-type APC also significantly upregulates FASN
and FASN itself is a major contributor to the pro-tumorigenic phenotype seen in
the APC/Villin-Cre mouse model.
To further investigate potential mechanisms behind FASN dependent
tumorigenesis, we analyzed these mouse tissues for global mRNA using RNAseq
analysis as well as performed metabolic analyses. Interestingly, we found that
FASN significantly regulates a spectrum of cellular processes. These include cell
cycle, cell proliferation, and multiple metabolic pathways. More specifically, we
found that FASN is associated with an increase in glycolysis and hexosamine
biosynthesis (glycosylation), with emphasis on the expression of two prominent
enzymes associated with glycosylation, GFPT1 and OGT. Upon further
investigation of the role these two enzymes might play in CRC, we showed that
OGT and GFPT1 themselves contribute to CRC proliferation, colony formation,
and tumorigenesis in vivo. This data suggests that FASN may help contribute to
APC-mediated CRC initiation through enhanced hexosamine biosynthesis and
altered glycosylation. Based on this data, our lab has been further investigating
the contribution of FASN to O-linked and N-linked glycosylation.
FASN, as previously mentioned, is already identified as a potential
therapeutic target for the treatment of CRC and several clinical trials are currently
underway using the FASN inhibitor TVB [191-193]. The data here suggests that
treatments targeting FASN may prove more effective if the CRC tissues contain a
mutation in APC. Additionally, targeting FASN in combination with hexosamine
biosynthesis may yield even greater treatment efficacy. Thus, we suggest that with
further investigation into FASN mediated tumorigenesis in CRC, from the
perspective of alterations in metabolic processes other than direct FA metabolism,
more effective treatment strategies for CRC may be developed.
5.7 Future Directions
Through a large variety of in vitro and in vivo methods as well as in human
tissues, we demonstrate a significant and specific upregulation of CD36 in the
presence of FASN inhibition or knockdown. However, the mechanistic drivers of
this upregulation have yet to be delineated. There are multiple upstream pathways
and effectors that can act on either FASN, CD36, or both. Both genes contain
sequences within their promoter regions which can be targeted by the sterolregulatory element binding proteins (SREBPs) as well as PPARs and STAT
proteins [200, 202, 336]. It is possible that in the absence of functionally de novo
lipid synthesis, one or some of these regulatory pathways and transcription factors
are upregulated in an attempt to compensate, leading to an increase in CD36
expression and an increase in exogenous FA uptake. In addition to transcriptional
regulation of CD36, it is worth noting that we observed an increase in membrane
bound CD36 when FASN was inhibited or knocked down. This suggests that there
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may be some post-transcriptional regulation of CD36 involved when de novo lipid
synthesis is reduced. As previously mentioned, palmitoylation of CD36 and the
presence of di-sulfide bridges within the protein are critical for subcellular
trafficking of CD36 the cell membrane and its association with lipid rafts [194].
Further investigation to the post-transcriptional regulation of CD36 when functional
FASN is reduced is necessary to fully delineate the association between these two
proteins that we describe in Chapter 2.
In addition to understanding the mechanistic link between CD36 and FASN,
further analysis of the translational effect of combining the inhibition of these two
proteins is necessary. We show that when we inhibit both FASN and CD36, we
see a combinational effect on decreased cell proliferation in multiple established
and primary cell lines. This in vitro data will need to be further elaborated on, by
transitioning to in vivo models with combinational treatment of both TVB and a
CD36 inhibitor. We reported in Chapter 2 that in vivo administration of SSO, an
inhibitor of CD36, significantly decreases subcutaneous xenograft tumor growth
but has no significant effect on animal body weight. This is encouraging and
suggests that a combination administration of both TVB and SSO may be
possible. There are companies actively developing inhibitors against CD36 with
clinical intent, such as Ona Therapeutics [334]. It is a possibility that if SSO proves
to be too toxic when used in combination with TVB in vivo, that novel inhibitors
may prove useful in such an investigation.
Although we demonstrate the important role CD36 plays in the proliferation,
tumorigenesis, and metastasis of CRC, more work is needed to delineate exact
mechanisms responsible for this phenomenon. One potential mechanism is the
direct uptake of exogenous FAs in the presence of increased CD36 expression,
leading to increased FA metabolism. We show in Chapter 2 that with increases in
CD36 expression, we observe an increase in the uptake of exogenous FA
analogues. However, the specific types of FAs up taken by CD36, and their fate
are not known.
There are several methods utilized today to study various metabolic
pathways which are enhanced in cancers cells. The cutting edge of these methods
is known as carbon-13 (13C) metabolic flux analysis [337]. This method involves
the labeling of a particular metabolic substrate, such as glucose or FAs, with a
stable isotope of carbon, such as 13C. When these molecules are metabolized by
the cell, the downstream metabolites are consequently labeled in a unique pattern
by the isotopes, which can be measured using techniques such as mass
spectrometry (MS) or nuclear magnetic resonance (NMR) [337]. Metabolic tracing
studies utilizing 13C labeled long-chain FAs of varying length could yield new
insights into the types of FAs CD36 uptakes in CRC and ultimately how those FAs
are utilized. Furthermore, Seahorse analysis of extracellular acidification rate
(ECAR) and oxygen consumption rate (OCR) on CRC cell lines utilized in Chapter
2-3, such as the CD36 knockdown and overexpression cell lines, is necessary to
determine if uptake of extracellular FAs via CD36 alters FA β-oxidation and
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glycolysis. These investigations will be critical in determining the role CD36 plays
in CRC tumorigenesis via direct increased exogenous FA uptake.
In addition to increased FA uptake and potentially an increased in FA
metabolism, we also observed as association between CD36 expression and that
of p-AKT and survivin. However, mechanistic links between CD36 expression and
increases in both survivin and p-AKT have not yet been delineated. Recently, it
has been shown that palmitic acid (PA) alone induces migration and invasion of
gastric cancer cells in a CD36 dependent manner [338]. Thus, PA treatment
studies in combination with altered expression or inhibition of CD36 in CRC could
determine if the increased activation of the AKT pathway and an increase in
survivin expression are directly related to exogenous PA up taken by CD36.
Aside from the pro-tumorigenic and proliferative properties of CD36 in CRC
that we describe here, we also demonstrate that CD36 significantly promotes CRC
metastasis. We showed that CD36 expression is associated with the newest
member of the matrix metallopeptidase family of proteins, MMP28, and that
MMP28 is associated with cleavage of e-cadherin. However, any direct
mechanistic link between CD36 expression and that of MMP28 remains elusive.
Being the most novel member of this family of proteins, resources on the MMP28
gene are limited, however, the gene has been sequenced. Other members of the
MMP family have promoter sequences for tumor necrosis factor alpha (TNFα) as
well as binding sites for NF-kB, signal transducers and activators of transcription
(STAT) proteins downstream of EGF signaling, and TGFβ [339-341]. Previous
studies in hepatocellular carcinoma have demonstrated that FFA treatment
promotes EMT in a CD36 dependent manner through increased activation of TGFβ
signaling [222]. In depth analysis of the promoter region of the MMP28 gene
sequence is necessary to identify potential enrichment sites for promoters, such
as TGFβ, that could potentially link MMP28 and CD36 mechanistically. Such future
investigations will shed new light on CD36 and its role not only in CRC and CRC
metastasis, but potentially yield new insight into roles CD36 may play in other
diseases.
Lastly, we show here that FASN promotes APC-driven tumorigenesis in
CRC and does so through the regulation of hexosamine biosynthesis. Further
investigation into the potential of targeting both de novo lipid synthesis and
hexosamine biosynthesis in combination will need to be performed both in vitro
and in vivo. Additionally, because of the significant reduction in tumor burden
observed in mice with FASN heterozygous knockout, it is possible to target FASN
via TVB in the APC/Villin-Cre mouse model to further investigate this phenomenon.
Analysis of current patient data basis for the expression patterns of both FASN
and mutant APC will need to be performed and could identify potential correlations
between these two genes and CRC patient prognosis. Together, the data
presented here and that of future investigations described could further delineate
the exact role FASN plays in CRC tumorigenesis and progression.
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5.8 Final Thoughts
CRC patients with distant metastatic disease are still in desperate need for
new therapeutic interventions. Stage IV CRC patients have severely low 5-year
survival rates and disease relapse is prominent amongst most patients.
Investigation into altered molecular and metabolic pathways that drive CRC
progression and metastasis is necessary to develop more effective treatments.
Altered FA metabolism is emerging as a prominent target for the treatment of CRC,
and studies from our lab have already demonstrated some of the importance that
de novo FA synthesis via FASN plays in CRC progression and metastasis. The
results of the studies described here also identify CD36, a prominent FA
transporter expressed in CRC, as a new potential therapeutic target for this
devastating disease. We further emphasize the striking relationship between
FASN and CD36, especially the upregulation of CD36 when FASN is effectively
inhibited. This is particularly important as TVB inhibitors against FASN are
currently in clinical trials. Aside from this compensation, we also describe the protumorigenic and metastatic properties of CD36 in the regulation of pro-survival
markers and e-cadherin cleavage via MMP28 and suggest that targeting CD36
could yield positive clinical results in CRC. Furthermore, we identified other protumorigenic properties of FASN, as shown using the APC/Villin-Cre mouse model
and how FASN can regulate cellular metabolism, particularly, hexosamine
biosynthesis.
Together, the data from the studies presented here offer new insights into
the complex regulation of FA metabolism in CRC. Further investigation into
mechanistic drivers behind CD36-mediated CRC progression and metastasis are
necessary to develop new chemotherapeutics. Additionally, further understanding
of CD36’s role in the compensation of FASN inhibition and the regulation of
glycosylation by FASN, could drastically improve the treatment efficacy of the
clinical trial drug TVB. Cumulatively, these studies show significant promise of
targeting lipid metabolism in the future development of treatment strategies for
CRC and beyond.
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Figure 5.1 Targeting Metastasis via FA uptake.
Schematic showing antibody targeting of CD36 as a potential therapeutic model
in cancer metastasis as described by Ona Therapeutics [334].
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APPENDICES
APPENDIX 1. METHODS FOR CHAPTER 2
Colon Cancer Established and Primary Cell Lines
Established cell lines HCT116, HT29, and HT29LuM3 were maintained in
McCoy’s 5A medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO)
and 1% penicillin–streptomycin. Primary colon cancer patient Pt 93 and Pt 130
cultures were isolated and established from PDX tumors as previously described
(1). Cells were maintained as monolayer culture in DMEM supplemented with 10%
FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–streptomycin. Primary Pt 93
and Pt 130 colon cancer cells were authenticated as unique human cell lines
(Genetica). Established CRC cell lines were authenticated using STR DNA
profiling (Genetica, Cincinnati, OH). Stable CD36 knockdown HCT116, HT29, and
HT29LuM3 cell lines were established using CD36 shRNAs from Sigma-Aldrich
(TRCN000005699, TRCN0000057000, and TRCN0000057001). Cells were
selected with 10mg/mL puromycin. Knockdown was confirmed via quantitative
real-time PCR (qRT-PCR) after cell selection and prior to performing animal
experiments. Overexpression cell lines were established by transfecting HCT116
cells with either pCMV-Spark-CD36 (Sino Biological Inc. NM 001001547.2), tdTomato-CD36 (Addgene, Plasmid #58077).
Tissue Microarray Analysis-Immunohistochemistry
Immunoreactivity scores of CD36 and FASN expression were analyzed in
matched normal colon mucosa and tumor tissues from patients diagnosed with
Stage I-IV CRC who had surgery at UK Chandler Medical Center (TMA ID
BH15991A, n = 56) by a GI pathologist (EYL) blinded as to tumor stage. The final
immunoreactivity score was determined by multiplication of the values for staining
intensity (0, no staining; 1, weak; 2, moderate; 3, strong staining) and the values
for percentage of positive tumor cells (0, no positive cells; 1, 0–10%; 2, 11–50%;
3, 51–100% positive).
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Tissue Collection
Tissues were obtained from consented patients with Stage II-IV CRC who
had undergone surgery at UK Medical Center (IRB #16-0439-P2H). 6–8-week-old
NSG mice (NOD.Cg-Prkdc Il2rg /SzJ) from The Jackson Laboratory (Bar Harbor,
ME) were used for PDX models. All procedures were performed using protocols
approved by the UK Animal Care and Use Committee. Briefly, CRC tissues (2–5
mm) obtained from CRC patients of both sexes were implanted subcutaneously
into their flanks in a small pocket surgically created under the skin. Established
tumors were designated as generation 0 (G0). Tumor tissues from G0 were minced
and mixed with Matrigel to ensure homogeneous distribution of tissues among
mice and allow implantation of an equal volume of tumor tissues into the flank.
Tumor tissues were resected when they reached an appropriate size and digested
as previously described [1]. For evaluation of CD36 expression in PDX models, we
utilized tissue samples from Pt 2402 PDX model established from a patient
diagnosed with metastatic adenocarcinoma (lung) consistent with colon primary
tumor [1]. Pt 2402 PDX tumors were grown to approximately 200 mm3 then tissues
were collected and lysed for analysis via western blot.
Flow Cytometry
Individual cells from PDX model Pt 2402 were stained for CD36 with
fluorescent antibody (Abcam ab23680). Stained cells were sorted via flow
cytometry and the top 10% of GFP positive CD36 expressing cells (CD36high) and
the bottom 10% of GFP negative cells (CD36low) were sorted separately from the
rest of the tumor cell population. CD36high and CD36low were mixed with 100 μL of
30% Matrigel and subcutaneously injected into NSG mice. Tumor growth was
monitored for three months. Samples were taken from subsequent tumors for
western blot analysis and immunohistochemistry and the remaining tumor tissue
was re-sorted for CD36.
FA Uptake
HCT116, NTC and FASN shRNA, cells were plated at 10,000 cells/well on
an 8-well coverslip u-slide (Ibidi #80826) and treated with CD36 neutralizing
antibody (Cayman Chemical #1009893) for 24 hrs. After incubation with
neutralizing antibody, cells were then treated with fluorescent FA analogue
BODIPY FL (Thermo Fisher #D3822) for 10 minutes in serum free McCoy’s 5A
medium supplemented with 10% FA free BSA. Cells were washed twice with PBS
and fixed with PBS containing 5% formalin for 20 minutes at 37C. Cell were then
imaged via confocal microscopy using a Nikon A1 Confocal Microscope.
Cell Proliferation Assay
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CRC cell lines were plated onto 24 well plates at a concentration of 30,000
cells per well. Cells were given DMEM medium for Pt 93 and Pt 130 and McCoy’s
5A medium for HCT116 with and without fetal bovine serum to simulate starvation
conditions. Cells were also treated with or without 100 μM SSO (Cayman
Chemical) or 0.2 μM TVB-3664 or both. TVB-3664 was provided by Sagimet
Biosciences (Menlo Park, CA).Cells were incubated at 37°C for 6 days. After the
incubation period, cells were trypsinized and collected individually based on well
and condition of treatment. Cells were counted using a Vi-Cell XR Cell Viability
Analyzer (Beckman Coulter #C19196). HCT116, NTC and CD36 shRNA (#2 and
#4), cells were plated onto 24 well plates at a concentration of 30,000 cells per
well. Cells were cultured in McCoy’s 5A medium with and without fetal bovine
serum for 72hr and counted as described above.
Quantitative Real-Time PCR
Total RNA was isolated using an RNeasy mini kit (QIAGEN). cDNA was
synthesized using a high-capacity cDNA reverse transcription kit (Applied
Biosystems). QRT-PCR was carried out using a TaqMan Gene Expression Master
Mix (#4369016) according to manufacture protocol and TaqMan probes for human
CD36 (ID Hs00354519 m1), human FASN (ID Hs01005622 m1), human FATP3
(ID Hs00354519 m1), human FATP4 (Hs00192700 m1) and human GAPDH
(#4333764F; Applied Biosystems).

Subcutaneous Xenografts
NU/NU mice were injected subcutaneously with 1.0 x 106 cells of HCT116
NTC (non-targeted control, n=7), shCD36 #2 (n=6) or shCD36 #4 (n=7) in 100 μL
PBS and tumor growth was monitored. Tumor size was measured via calipers
every three days and tumor volume was calculated using the formula: TV = width2
x length / 0.52. When NTC tumor growth reached approximately 200 mm3, all mice
were sacrificed, and tumor weight was taken via digital scale. NU/NU mice were
injected subcutaneously with 2.0 x 106 cells of NTC (n=5) and shCD36 #4 (n=5) in
100 μL PBS for HT29 and HT29 LuM3 xenografts experiments.
Genetically Modified Mice
C57BL/6J mice with LoxP-flanked FASN alleles were obtained from Clay
Semenkovich, MD at Washington University, and FASN/VillinCre and
FASN/Apc/VillinCre mouse colonies were established by mating these mice with
C57BL/6J Villin/Cre and C57BL/6J Apc/Cre mice in Dr. Zaytseva’s laboratory
[128].
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APPENDIX 2. METHODS FOR CHAPTER 3
Colon Cancer Established and Isogenis Cell Lines
Established cell lines HCT116, HT29, and HT29LuM3 were maintained in McCoy’s
5A medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1%
penicillin–streptomycin. HT29 LuM0 and LuM3 cell lines were established as
previously described [254]. Stable CD36 knockdown HCT116, and HT29LuM3 cell
lines were established using CD36 shRNA from Sigma-Aldrich
(TRCN0000057001). Cells were selected with 10mg/mL puromycin. Knockdown
was confirmed via quantitative real-time PCR (qRT-PCR) after cell selection and
prior to performing in vitro and in vivo experiments. Overexpression cell lines were
established by transfecting HCT116 and HT29 LuM0 cells with either pLenti-CMyc-DDK-P2A-Puro-CD36 overexpression (OriGene # RC221976L1V) or pLentiC-Myc-DDK-P2A-Puro-Empty-Vector
(OriGene
#PS1000064)
lentiviral
transduction particles. MMP28 knockdown cell lines were generated by
transfecting HCT116 cells with siMMP28 siRNA (Invitrogen #87705767) or
scrambled siRNA control in combination with Lipofectamine RNAiMAX
Transfection Reagent (Thermo Fisher #13778150). MMP28 knockdown was
verified by qRT-PCR and western blot. Cells were transfected for 48hrs prior to in
vitro experiments performed.
Quantitative Real-Time PCR
Total RNA was isolated using a RNeasy mini kit (QIAGEN). cDNA was
synthesized using a high-capacity cDNA reverse transcription kit (Applied
Biosystems #4368814). QRT-PCR was carried out using a TaqMan Gene
Expression Master Mix (Applied Biosystems #4369016) according to manufacture
protocol and TaqMan probes for human CD36 (Thermo Fisher #4331182Hs00169627_m1), MMP28 (Thermo Fisher #4331182-Hs00425232_g1), ecadherin/CDH1 (Thermo Fisher #4331182-Hs01023895_m1), and GAPDH
(Thermo Fisher #4331182-Hs02786624_g1).
Trans-Well Invasion Assay
HCT116 CD36 Overexpressing and CD36 knockdown cell lines were plated
and starved for 48hrs on 100 mm petri dishes with McCoy’s 5A medium without
FBS supplementation. Corning 24-well BioCoat™ Matrigel® Invasion Chambers
(Corning # 354480) were rehydrated for 2hrs with McCoy’s 5A medium not
supplement with FBS at 37C. HCt116 cell lines were then trypsinized and counted
using a Beckman Coulter Vi-Cell BLU Cell Viability Analyzer (Beckman Coulter
#C19196) and plated at 50,000 cells/chamber in serum free with McCoy’s 5A
medium. Invasion chambers were then placed in wells containing 400 uL of
McCoy’s 5A medium supplemented with 10% FBS as a chemoattractant. Cell were
allowed to invade for 48hrs. Chambers were then aspirated, the inside wiped with
a cotton swab, and chambers stained with 0.1% crystal violet (Millipore sigma
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#C6158-50G) for 10 minutes. Chambers were imaged and then de-stained using
extraction buffer from the CytoSelect Cell Invasion Assay Kit (Cell Biolabs Inc. #
CBA-111-T). Extracts were plated on a 96 well plate and absorbance was
measured at 560 nm on a microplate reader for cell invasion quantification.
Colony Formation Assay
6-well cell culture plates were first layered with 2% soft agar using
SeaPlaqueTM GTG Agarose (Lonza #50115) melted in Milli-Q water. HCT116 and
HT29 LuM0 CD36 overexpressing cells were tripsinized and counted as described
above. Cells were mixed with a 1.5% soft agar and 2X McCoy’s 5A medium
solution and plated at a concentration of 5,000 cells/well. McCoy’s 5A medium
supplemented with 10% FBS was placed on top of both agarose layers and media
levels monitored. Colonies were allowed to grow for 14 days then stained with
0.1% crystal violet (Millipore sigma #C6158-50G) for 2hrs at room temperature.
Wells were then washed with Milli-Q water to remove excess crystal violet stain
then imaged and colony diameter measured.
Confocal Microscopy
HT29-GFP-Luc. LuM0 and LuM3 cells were plated at a concentration of
10,00 cells/chamber onto u-Slide 8 well chambered coverslips (Ibidi #80826) in
400ul McCoy’s 5A medium supplemented with 10% FBS for 48hrs. Cells were then
fixed with 10% Formalin for 10 minutes followed by permeabilization with 1% Triton
X. Cells were then blocked with 1% bovine serum albumin (BSA) for 20 minutes at
room temperature. Cells were incubated with primary antibodies for CD36 (Santa
Cruz # sc-7309), and MMP28 (Abcam #ab175937) in 1% BSA for 2hrs at room
temperature. Cells were then washed 3X with PBS and incubated with fluorescent
secondary antibodies (Invitrogen #A11032 and # A32728) in 1% BSA for 1hr at
room temperature. Chambers were washed 3X with PBS and incubated with
Hoechst and Phalloidin stains for 20 minutes. Chambers were then imaged using
a Nikon A1 Confocal Microscope.
FA Uptake Assay
HT29-GFP-Luc. LuM0 and LuM3 cells were plated at 10,000 cells/well on
an 8-well coverslip u-slide (Ibidi #80826) and treated with CD36 neutralizing
antibody (Cayman Chemical #1009893) for 24 hrs. After incubation with
neutralizing antibody, cells were then treated with fluorescent FA analogue
BODIPY ™ 558/568 C12 (Thermo Fisher # D3835) for 10 minutes in serum free
McCoy’s 5A medium supplemented with 10% FA free BSA. Cells were washed
twice with PBS and fixed with PBS containing 5% formalin for 20 minutes at 37C.
Cell were then imaged via confocal microscopy using a Nikon A1 Confocal
Microscope.
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Tail-Vein Injections
HT29-LuM3-GFP-Luc. NTC (n=5) and shCD36 (n=5) cell lines were
aliquoted into PBS at a concentration of 1.0x10^6 cells/100ul and injected via tailvein into 6–8-week-old NSG mice (NOD.Cg-Prkdc Il2rg /SzJ). After 9 weeks, lung
colonization was first imaged via a luciferase reporter assay and a Lago Spectral
Imaging System (Lago SII). Live mice were administered 100ul of D-luciferin at a
concentration of 3mg D-luciferin/20kg mouse via intraperitoneal injection. After 10
minutes, mice were imaged, and bioluminescent signal was quantified using the
Lago SII. After live imaging, mice were sacrificed, and lungs resected and imaged
for GFP signal. Lung tissues were processed for immunohistochemistry (IHC) as
described below.
Cecum Injections
Cecum injections were performed as previously described [299]. HCT116
CD36 overexpression (n=5) and Control (n=5) cells were aliquoted in PBS at a
concentration of 1.0x10^6 cells/50ul and injected into the cecal wall of NU/NU
mice. After 10 weeks, mice were sacrificed and imaged for tumor burden within the
cecum, colon, and intestine. Cecum tissues were collected for IHS as described
below.
RNA-Seq and Gene Enrichment Analysis
RNA samples extracted from HT29-LuM0-GFP-Luc. Control and CD36
Overexpression cell lines were analyzed via RNA-Seq by BGI Genomics,
Cambridge, MA. Gene enrichment analysis was performed on HT29-LuM0-GFPLuc. Control and CD36 Overexpression cell lines by the Biostatistics and
Bioinformatics Shared Resource Facility at the University of Kentucky, Lexington,
KY.

APPENDIX 3. METHODS FOR CHAPTER 4
Mouse Strains
C57BL/6J mice with LoxP-flanked FASN alleles were obtained from Clay
Semenkovich, MD at Washington University and FASN/VillinCre, FASN+/∆
/Apc/Villin-Cre and FASN∆/∆ /Apc/Villin-Cre mouse colonies along with their ERT2
derivatives were established in Dr. Zaytseva’s laboratory.
Animal Survival Studies
Wild type and FASN heterozygous knockout mouse strains, both male and
female, monitored for survival. Mice were sacrificed near experiment termination
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and their life span in days was counted. Tissues were collected for imaging of
tumor burden. Number of adenomas was counted within 10 cm of small intestine
(starting) 1 cm from the cecum. Swiss rolls were prepared to confirm histology and
perform IHC on FASN, Ki67 and other markers. qRT-PCR and western blot
analysis were used to asses FASN expression.
Metabolite Extraction
Isolated tumors from mouse strains described above were removed from
cryostorage and transferred to a mircovial set for use with a Freezer/Mill Cryogenic
Grinder (SPEX SamplePrep model 6875D). Tissue was pulvierzied to 5um
particles. Metabolites were extracted directly from the microvial by the addition of
1 ml of 50% methanol containing 20 M L-norvaline (procedural, internal control)
and separated into polar (aqueous layer) and insoluble pellet
(protein/DNA/RNA/glycogen) by centrifugation at 4°C, 15,000rpm for 10 minutes.
The pellet was subsequently washed four times with 50% methanol and once with
100% methanol to remove polar contaminants. The pellet was then hydrolyzed in
200ul of 3N hydrochloric acid and then neutralized with 200ul of 100% methanol.
The polar and pellet fraction was dried at 10-3 mBar using a SpeedVac (Thermo
Fisher) followed by derivatization. The insoluble pellet was hydrolyzed similar to
the technique described in [342].
Sample Derivatization and Gas Chromatography-Mass Spectrometry
Quantificantion
Dried polar and insoluble samples were derivatized by the addition of 50ul
20 mg/ml methoxyamine hydrochloride in pyridine, vortexed thoroughly and
incubated for 1.5 hrs at 30°C. Sequential addition of 80ul of N-methyl-trimethylsilyltrifluoroacetamide (MSTFA) followed with an incubation time of 30 minutes at 37°C
with thorough vortexing between addition of solvents. The mixture was then
transferred to an amber, v-shaped glass chromatography vial and analyzed by
GCMS.
An Agilent 7800B gas-chromatography coupled to a 5977B mass
spectrometry (GCMS) detector was used for this study. GCMS protocols were
similar to those described previously[343, 344] except a modified temperature
gradient was used for GC: Initial temperature was 130C, held for 4 minutes, rising
at 6C/minutes to 243C, rising at 60C/minutes to 280C, held for 2 minutes. The
electron ionization (EI) energy was set to 70 eV. Scan (m/z:50-800) and full scan
mode were used for metabolomics analysis. Mass spectra were translated to
relative metabolite abundance using MassHunter MS quantitative software
matched to the FiehnLib metabolomics library (available through Agilent) for
retention time and fragmentation pattern[344-346]. Relative abundance was
corrected for recovery using the L-norvaline standard and adjusted to protein input
represented by the sum of amino acids from the pellet fraction also analyzed by
GCMS.
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Reverse Phase Protein Array
The RPPA was performed by the Redox Metabolism Shared Resource
Facility at The University of Kentucky. The raw RPPA data from mouse tissues
described above was obtained in 6 dilution steps and was processed based on the
following procedure. Firstly, data quality control was performed by plotting the
relationship between background corrected intensity and dilution step. Proteins
with low measurement quality as reflected by large variation across replicates or
unreliable curve trend were excluded. Secondly, nonlinear curve fitting for the
background corrected intensity vs dilution step was applied based on the “serial
dilution curve” algorithm [347] to infer the concentration of each protein in the
original undiluted sample. Due to the low protein concentration measurement in
the 6th dilution step, the nonlinear curve fitting was only based on data from the
first 5 dilution steps. Thirdly, protein concentrations were log2-transformed and
normalized based on the median normalization method as described in [348] and
[349]. Finally, the Wilcoxon Rank Sum test was used for differential expression
analysis comparing between experimental groups. Multiple comparisons
adjustment was performed by the Benjamini and Hochberg method. Differentially
expressed proteins were identified by false discovery rate < 0.05. Heatmap and
volcano plots were generated to demonstrate the relative expression changes of
proteins of interest.
RNA-Seq and Gene Enrichment Analysis
RNA samples extracted FASN/VillinCre and FASN+/∆ /Apc/Villin-Cre were
analyzed via RNA-Seq by BGI Genomics, Cambridge, MA. Gene enrichment
analysis was performed on these same tissues by the Biostatistics and
Bioinformatics Shared Resource Facility at the University of Kentucky, Lexington,
KY.
Colon Cancer Established and Primary Cell Lines
The established cell line HCT116 was maintained in McCoy’s 5A medium
supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–
streptomycin. HCT116 NTC, shGFPT1, and shOGT were stablishged via
transfection of lentiviral particles targeting GFPT1, OGT, or non-targetd control (
). Cells were selected with 10mg/mL puromycin. Knockdown was confirmed via
quantitative real-time PCR (qRT-PCR) after cell selection and prior to performing
animal experiments. Primary colon cancer patient Pt 93 and Pt 130 cultures were
isolated and established from PDX tumors as previously described (1). Cells were
maintained as monolayer culture in DMEM supplemented with 10% FBS (SigmaAldrich, St. Louis, MO) and 1% penicillin–streptomycin. Primary Pt 93
colon cancer cells were authenticated as unique human cell lines (Genetica).
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Cell Proliferation Assay
Pt93 cells were plated onto 24 well plates at a concentration of 30,000 cells
per well in DMEM medium with 10% FBS and 1% penicillin–streptomycin Cells
were treated with varying concentrations of azaserine (Millipore Sigma #A414250MG) or OSMI1 (Millipore Sigma #SML1621-5MG). Cells were incubated at 37°C
for 48 hrs. After incubation period, cells were trypsinized and collected individually
based on well and condition of treatment. Cells were counted using a Vi-Cell XR
Cell Viability Analyzer (Beckman Coulter #C19196).
Colony Formation Assay
6-well cell culture plates were first layered with 2% soft agar using
SeaPlaqueTM GTG Agarose (Lonza #50115) melted in Milli-Q water. Pt93 cells
were tripsinized and counted as described above. Cells were mixed with a 1.5%
soft agar and 2X McCoy’s 5A medium solution and plated at a concentration of
5,000 cells/well. McCoy’s 5A medium supplemented with 10% FBS and containing
20uM of either azaserine or OSMI-1, was placed on top of both agarose layers and
media levels monitored. Colonies were allowed to grow for 14 days then stained
with 0.1% crystal violet (Millipore sigma #C6158-50G) for 2hrs at room
temperature. Wells were then washed with Milli-Q water to remove excess crystal
violet stain then imaged and colony diameter measured.
Quantitative Real-Time PCR
Total RNA was isolated using a RNeasy mini kit (QIAGEN). cDNA was
synthesized using a high-capacity cDNA reverse transcription kit (Applied
Biosystems #4368814). QRT-PCR was carried out using a TaqMan Gene
Expression Master Mix (Applied Biosystems #4369016) according to manufacture
protocol and TaqMan probes for human FASN (Thermo Fisher #4331182Hs01005622_m1), GFPT1 (Thermo Fisher #4331182-Hs00899865_m1), OGT
(Thermo Fisher #4331182-Hs00269228_m1), and GAPDH (Thermo Fisher
#4331182-Hs02786624_g1).

Subcutaneous Xenografts
NU/NU mice were injected subcutaneously with 1.0 x 106 cells of HCT116
NTC (non-targeted control, n=5), shGFPT1 (n=5) or shOGT (n=7) in 100 μL PBS
and tumor growth was monitored. Tumor size was measured via calipers every
three days and tumor volume was calculated using the formula: TV = width2 x
length / 0.52. When NTC tumor growth reached approximately 200 mm3, all mice
were sacrificed, and tumor weight was taken via digital scale.
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